Comprehensive Invited Review

Redox Regulation of Multidrug Resistance in Cancer Chemotherapy: Molecular Mechanisms and Therapeutic Opportunities

Macus Tien Kuo

*Reviewing Editors: Patrick Bednarski, Kimitoshi Kohno, Milena Salerno,
Jolanta Tarasiuk, and Franco Zunino*

I.	Introduction	100
II.	Structure and Function of Multidrug-Resistance Transporter Protein Families	101
	A. MDR/Pgp family	101
	B. MRP/GS-X pump family	102
	C. BCRP/ABCG2	102
	D. Non-ABC multidrug-resistance proteins	103
III.	Redox Regulation of Multidrug-Resistance Transporters: Conformational Changes of the Transporters	103
IV.	Redox Regulation of Multidrug-Resistance Transporter Activity	104
V.	Redox Regulation of Multidrug-Resistance Transporter Gene Expression	105
	A. MDR/Pgp family	105
	1. Transcriptional regulation	105
	2. Posttranscriptional regulation	108
	3. Epigenetic regulation	108
	B. γ -Glutamylcysteine synthetase (γ -GCS)	109
	1. Transcriptional regulation	110
	2. Posttranscriptional regulation	111
	C. MRP family	112
	D. BCRP/ABCG2	112
VI.	Redox Regulation of Multidrug-Resistance Transporters: Gene Amplification	113
	A. Role of redox signaling in chromosomal breakage at fragile sites	114
	B. Role of redox signal in sister chromatid fusion	115
VII.	Redox Signaling in the Evolution of Intrinsic Multidrug Resistance in Cancer	115
	A. Evolution of intrinsic multidrug resistance (upfront resistance)	115
	B. Signal-transduction pathways in the intrinsic multidrug resistance	116
	1. The NF- κ B pathway	116
	2. The PI3 kinase pathway	117
	3. The p53 pathway	117
VIII.	Clinical Significance of Redox Signaling in Multidrug Resistance and Therapeutic Opportunities	117
IX.	Redox Signaling in Multidrug-Resistant Cancer Stem Cells	119
	A. Multidrug-resistant hemopoietic stem cells	119
	B. Multidrug-resistant cancer stem cells of solid tumors	119

C. Signaling pathways in cancer stem cells	120
1. The Wnt/ β -catenin signaling	120
2. The Notch signaling	121
3. The sonic hedgehog signaling	121
X. Therapeutic Opportunities for Cancer Stem Cells	121
XI. Conclusions: Challenges and Perspectives	122

Abstract

The development of multidrug resistance to cancer chemotherapy is a major obstacle to the effective treatment of human malignancies. It has been established that membrane proteins, notably multidrug resistance (MDR), multidrug resistance protein (MRP), and breast cancer resistance protein (BCRP) of the ATP binding cassette (ABC) transporter family encoding efflux pumps, play important roles in the development of multidrug resistance. Overexpression of these transporters has been observed frequently in many types of human malignancies and correlated with poor responses to chemotherapeutic agents. Evidence has accumulated showing that redox signals are activated in response to drug treatments that affect the expression and activity of these transporters by multiple mechanisms, including (a) conformational changes in the transporters, (b) regulation of the biosynthesis cofactors required for the transporter's function, (c) regulation of the expression of transporters at transcriptional, posttranscriptional, and epigenetic levels, and (d) amplification of the copy number of genes encoding these transporters. This review describes various specific factors and their relevant signaling pathways that are involved in the regulation. Finally, the roles of redox signaling in the maintenance and evolution of cancer stem cells and their implications in the development of intrinsic and acquired multidrug resistance in cancer chemotherapy are discussed. *Antioxid. Redox Signal.* 11, 99–133.

I. Introduction

THE CONSTANT ASSAULT by environmental toxic substances over the evolutionary time has made it necessary for living organisms to develop mechanisms to avoid the deleterious effects of these cytotoxic compounds. Among the many important detoxification mechanisms, one that involves efflux pumps that actively eliminate toxic substances from inside the cells has been widely documented from bacteria to mammals. As many antitumor agents are derived from natural products, overexpression of these efflux pumps in cancer cells represents a major mechanism of drug resistance in cancer chemotherapy. What is intriguing is that most often, upregulation of a single efflux pump is associated with the development of pleiotropic resistance to a wide spectrum of structurally and functionally unrelated anticancer drugs. In mammalian cells, this multidrug-resistance phenotype was first observed ~30 years ago. When cultured cells were exposed to a single cytotoxic agent, the resulting drug-resistant variants exhibited collateral resistance to a broad spectrum of cytotoxic agents [for reviews, see (31, 95, 134)]. These cytotoxic agents shared little similarity in their chemical structures or modes of cytotoxicity. Molecular cloning and functional characterizations revealed that a single transmembrane protein named P-glycoprotein (Pgp) or multidrug transporter 1 (MDR1) was sufficient to give rise to the multidrug-resistance phenotype. It was later realized that MDR1/Pgp alone could not account for all the multidrug resistance in many independently established multidrug-resistant cells, which led to the discoveries of other multidrug resistance-related transporters, notably multidrug resistance-associated protein (MRP1) and breast cancer-resis-

tance protein (BCRP). Amino acid sequence analyses revealed that all these multidrug-resistance proteins contain multiple transmembrane domains (TMDs) and intracellularly localized ATP binding cassette (ABC) (Fig. 1). These multiple TMDs form a pore whereby animal cells use the intracellularly localized ABC to hydrolyze ATP to provide an energy source to eliminate cytotoxic compounds outward and reduce intracellular drug content to a sublethal level. Thus, these multidrug transporters belong to the ABC-transporter superfamily.

The human genomic sequencing project revealed that humans have 49 ABC transporters (<http://www.gene.ucl.ac.uk/nomenclature/genefamily/abc.html> or <http://www.nutrigen.4t.com/humanabc.htm>). These 49 ABC transporters have been classified into seven groups (*i.e.*, ABCA1-ABCA12, ABCB1-ABCB11, ABCC1-ABCC13, ABCD1-ABCD4, ABCE1, ABCF1-ABCF3, and ABCG1-ABCG5). Their primary amino acid sequences define their chemical structures and their substrate specificities. Many of these ABC transporters are multidrug transporters of cancer chemotherapeutics.

Reactive oxygen species (ROS), including oxyl radicals such as superoxide anion [$O_2^{\cdot-}$], hydroxy radical [$\cdot OH$], and hydrogen peroxide [H_2O_2], are generated endogenously by all aerobic cells as byproducts of many metabolic reactions. Mitochondria form the major powerhouse of ROS production; they are generated in association with the activity of the respiratory chain [*e.g.*, NADH dehydrogenase enzyme complexes (278)] in aerobic ATP production. In addition, two classic phagocytic ROS-generating enzymes use molecular oxygen as a substrate, including the multisubunit NADPH oxidase and its homologue NOX/Duox family (140), and myeloperoxidase (70) in various tissues in response to ex-

FIG. 1. Schematic diagrams showing the structure of various ABC transporters. MRP1, 2, 3, 6, and 7 each contain 17 transmembrane (TM) motifs distributed into three membrane-spanning domains (MSDs), whereas MDR1, MDR2, and MRP4, 5, 8, and 9 have 12 TMs in two MSDs, and ABCG2 has six TMs in one MSD. All these proteins are ABC transporters that containing intracellularly localized ATP-binding cassettes (ABCs).

tracellular influences (123). Other sources of ROS production include the cytochrome P450 (CYP450) system, which is involved mainly in removing or detoxifying toxic substances in the liver; xanthine oxidase, which catalyzes the oxidation of hypoxanthine to xanthine with the formation of H_2O_2 ; and nitric oxide synthase, which catalyzes a five-electron oxidation of a guanidino nitrogen of L-arginine in the formation of citrulline and nitric oxide.

Under normal physiologic conditions, a balance exists between oxidants and antioxidants: a reduction–oxidative (redox) homeostasis. ROS at submicromolar levels act as second messengers to stimulate cell proliferation, apoptosis, and gene expression. Endogenously elevated ROS are handled by antioxidants produced by a host of intracellular enzymes, such as superoxide dismutase (SOD), glutathione peroxidase (GPx), catalase, and thioredoxin reductase (Trx) and the alpha class of glutathione S-transferase, which can decompose lipid hydroperoxides and hydrogen peroxide (237). Excessive levels of ROS produce oxidative stress that leads to a variety of diseases, including neurologic disorders, aging, and cancer. Moreover, oxidative stress can affect the efficacy of cancer treatments by multiple mechanisms, including chemosensitivity, apoptosis, angiogenesis, metastasis, inflammatory reaction, and chemosensitivity. In this review, the effects of redox signals on drug resistance, specifically on multidrug resistance encoded by a subset of ABC transporters, are presented.

II. Structure and Function of Multidrug-Resistance Transporter Protein Families

A. MDR/Pgp family

MDR belongs to the B group of the ABC transporter superfamily. Two Pgp-encoded MDR genes have been found in humans, MDR1 (ABCB1) and MDR2 (ABCB2). These membrane proteins contain two core membrane-spanning domains, MSD1 and MSD2, each of which consists of six transmembrane domains (TMDs) (Fig. 1). The two MSDs are separated by the first ABC. The second ABC is located at the C-terminus. Many review articles have described the structural and functional aspects of MDR1-encoding P-glycoprotein (Pgp) (31, 95, 133, 229). A brief background review relevant to the subjects of the present review follows.

The human MDR1 gene is expressed in many normal tis-

sues, including the liver, kidney, small intestine, colon, adrenal gland, and the blood–brain barrier, whereas MDR2/Pgp2 is expressed mainly in the liver and kidney. The endogenous substrates of Pgp1 remain to be determined, whereas Pgp2, which is expressed mainly in the liver canalicular compartment, functions as a phospholipid transporter. Only Pgp1 functions as an antitumor drug transporter for doxorubicin, vincristine, and taxanes, etoposide, teniposide, actinomycin D, etc. These substrates, although structurally dissimilar, are generally hydrophobic. It is believed that these agents enter the cells through passive diffusion due to a drug concentration gradient across the membrane and are eliminated against the concentration gradient by Pgp1 by using its intracellularly located nucleotide-binding domain (NBD) to hydrolyze ATP as an energy source. However, the molecular mechanism by which a single multispecific membrane protein can transport such a structurally diverse spectrum of antitumor agents has been a challenging topic since the completion of molecular cloning of MDR gene.

Because it has been unusually difficult to obtain the detailed molecular structure of drug-transporter proteins, owing to protein purification and crystallization of membrane proteins, the molecular basis of transport mechanisms remains largely unknown. Nonetheless, crystallographic information has become available from a bacterial homologue of multidrug transporter MsbA, providing instrumental information in elucidating the transport mechanism of Pgp (95). This information, together with studies using biochemical approaches (31), suggests that the initial event in Pgp-mediated drug transport is substrate binding, which leads to conformational changes that bring the two NBDs into close proximity to facilitate ATP binding. Nucleotide binding and subsequent ATP hydrolysis provide the energy needed to release the substrate outward through the multi-TMD-forming pore. Nonetheless, the detailed dynamic and vectorial processes involved remain largely unknown.

Mice have three *mdr* genes, two of which (*mdr1a* and *mdr1b*) are multidrug transporters, whereas the third (*mdr2*) has a function similar to that of human MDR2. Like those in the human counterparts, the endogenous substrates for *mdr1a* and *mdr1b* are not known. Mutant *mdr1a*(–/–) mice or compound *mdr1a*(–/–)*mdr1b*(–/–) mutant mice generated by knockout strategies are viable and fertile, suggesting that *mdr1a* and *mdr1b* are not essential for cell viability

(225, 226). However, these animals exhibit elevated sensitivity to the effects of cytotoxic agents. In this context, it is considered that animals use these efflux pumps to prevent accumulation of xenobiotics from various organs, thereby performing detoxification functions.

B. MRP/GS-X pump family

Nine members of the multidrug-resistance protein (MRP) family are found in the human genome, designated MRP1 through MRP9, corresponding to ABCC1 through ABCC6 and ABCC10 through ABCC12, respectively. Among the nine members, MRP4, MRP5, MRP8, and MRP9 have topologic configurations similar to those of MDR1 and MDR2 (Fig. 1), whereas MRP1, 2, 3, 6, and 7 have an additional membrane-spanning domain, called MSD₀, located at the N-terminus. Topologically, MSD₀ is not essential for the catalytic function of MRP1, because deleting this domain did not compromise its substrate-transport activity (14). However, studies show that mutations at certain Cys residues within MSD₀ drastically reduce substrate-transport activities (153, 283), and a photoaffinity labeling study demonstrated that MSD₀ interacts with a photoreactive azido analogue of leukotriene C4 (LTC4) (121), suggesting that MSD₀ may not be entirely functionless. A recent study suggests that the N-terminal amino acid residues may function as a plug that controls the gating during drug transport mediated by the transporter (47). Many review articles regarding MRPs have already been published (31, 59, 131, 134). Only those that are most relevant to the current subject will be concisely discussed.

MRP1 was the first one in the family identified from a doxorubicin-resistant human cell line that did not overexpress MDR1/Pgp1 (52). The expression pattern of MRP1 is ubiquitous. Overexpression of MRP1 confers resistance to a spectrum of antitumor agents that is similar, but not identical, to that of Pgp1. Taxanes are good substrates for MDR but are poor substrates for MRP1. MRP2 has a substrate selectivity similar to that of MRP1, but the tissue-expression profile is quite different from that of MRP1. MRP2 expression is restricted to the liver and kidney. These tissues contain polarized cells. MRP2 is localized on the apical surface, predominantly in the canalicular membrane of hepatocytes. Its major physiologic function is to mediate ATP-dependent transport of glutathione (GSH) and glucuronate conjugate metabolites into the bile canaliculus in the livers. Both MRP1- and MRP2-mediated efflux require cofactors, glutathione GSH, glucuronic acid, or sulfate. MRP1 transports GSH conjugates such as LTC4, prostaglandin A2-SG, glucuronide conjugates such as 17 β -estradiol-17- δ -glucuronide, and sulfate conjugates such as estron 3-sulfate sulfatolithocholate. Mice lacking *mrp1* are viable and fertile but have a defect in inflammatory response to the mediator LTC4, which is an endogenous substrate of *mrp1* (274). Animals with impaired *mrp2* expression showed defects in hepatobiliary extrusion of bilirubin glucuronide and developed the Dubin-Johnson syndrome (120).

The structural organization of MRP3 is similar to that of MRP1 and MRP2, but the substrate specificity of MRP3 is quite different from those of MRP1 and MRP2. MRP3-mediated transport does not require intracellular GSH. Moreover, in the liver, MRP2 is expressed in the canalicular com-

partment, whereas MRP3 is expressed in the basolateral membrane. MRP3 may be the major transporter involved in the basolateral transport of organic anions in the liver, because animals deficient in *mrp3* have defective transport of morphine-3-glucuronide from the liver into the bloodstream (289). Etoposide appears to be transported by MRP3 in unmodified form (288), whereas vincristine and doxorubicin, which are transported by MRP1 and MRP2 (but require no glutathionation with the drugs), are not transported by MRP3.

MRP4 and MRP5 contain 12 TMDs rather than 17 TMDs, making them structurally more like MDR1 than like MRP1. Cyclic nucleotides and their analogues are substrates of MRP4 (228) and MRP5 (206, 221) but not of MRP1, MRP2, or MRP3. MRP4 is expressed in the basolateral membrane of the choroid plexus epithelium and in the brain capillary endothelium. In *mrp4*(-/-) animals, the movement of topotecan from the blood into the brain tissue and cerebrospinal fluid is effectively limited, resulting in the accumulation of topotecan in the brain (145). These results suggest that MRP4 transports not only cyclic nucleotides but also antitumor agents and that MRP4 may have therapeutic value that targets the central nervous system.

MRP6 and MRP7 share structural similarities with MRP1 and MRP2 topologically. Like MRP2, MRP6 is expressed primarily in the liver and kidney. Expression of the MRP7 gene is ubiquitous but is high in the pancreas in the adult and fetal tissues. Increased MRP7 expression was detected in doxorubicin-treated MCF7 cells, suggesting that it is involved in resistance to antitumor agents. It has been demonstrated that MRP6 is capable of transporting GSH-conjugates such as LTC4 and DNP-GSH but not glucuronide conjugates such as E217 β G, suggesting that MRP6 is a GS-X pump (131). The roles of GSH in the function of these transporters have not been as well characterized as those of other MRP transporters. Animals with ablated *mrp6* by knockout technology develop mineralization in connective skin, resembling the pseudoxanthoma elasticum syndrome (126). However, the molecular basis for the role of MRP6 in this disease is not clear.

MRP8 and MRP9 genes are tandemly located in a tail-to-head orientation on human chromosome 16q12.1. The predicted amino acid sequences of both gene products show a high degree of similarity with MRP4 and MRP5, suggesting that the substrate specificities would be related to those of MRP4 and MRP5. This indeed has been the case. Ectopic expression of MRP8 in mammalian cells enhances cellular efflux of cyclic nucleotides and confers resistance to certain anticancer and antiviral nucleotide analogues (84). Interestingly, a single-nucleotide polymorphism in MRP8 (G538A) is associated with the dry-earwax phenotype in humans, and GA and GG, with the wet type (286) and colostrum and cerumen secretion (177). Recently, full-length MRP9 has been cloned. Expression of MRP9 was not detected in many human tissues except in the midpiece of sperm (192). The function of MRP9 and the identity of its substrate remain to be investigated.

C. BCRP/ABCG2

Human BCRP, also called mitoxantrone-resistance protein (MXR), belongs to ABCG2. It was first cloned from the dox-

orubicin-resistant MCF-7 breast cancer cell line in the presence of a Pgp inhibitor (5, 65, 178). This transporter encodes only 655 amino acids, about one-half of the size of MDR1 or MRP transporter (Fig. 1). It is thus likely that two half-molecules form a homodimer to function as a drug transporter. BCRP transports a diverse array of substrates including mitoxantrone, topotecan, doxorubicin, and SN-38, which overlap those of Pgp1 and MRP1 (20, 130, 271). It has been demonstrated that porphyrin and porphyrin-like compounds are natural substrates of BCRP (115). Imatinib (Gleevec) (100) and gefitinib (Iressa) (193), two important tyrosine kinase inhibitors developed for the treatment of chronic myeloid leukemia (CML), bearing p210Bcr-Abl abnormality, are also inhibitors of BCRP-mediated transport activities. BCRP apparently does not require GSH cofactor for transport. Like *mdr1a*(-/-), *mdr1b*(-/-), and *mrrp*(-/-) mice, *bcrp*(-/-) animals are fertile with no apparent phenotypic alterations as compared with those in the wild-type animals, but are extremely sensitive to the pheophorbide a, a phototoxic porphyrin catabolite of chlorophyll (115). Furthermore, *bcrp*(-/-) animals also show increased fatal accumulation of topotecan (115). Because BCRP is expressed mainly in the placenta, it is suggested that BCRP may control the penetration of drugs from the maternal plasma into the fetus.

D. Non-ABC multidrug-resistance proteins

Another GSH-conjugate transporter, Ral-binding protein 1 (RLIP76/RALBP1), is a Ral-regulated protein that belongs to Rho family GTPases. Membrane-associated RLIP76 functions as a multispecific efflux pump for antitumor agents in vinca alkaloids and anthracyclines (9). RLIP76 appears to be a stress-response protein that provides protection from oxidative stress induced by these compounds.

Many reports have described the association of lung resistance-related protein (LRP) with non-Pgp-mediated multidrug-resistant phenotypes in human cancer cell lines. LRP is related to major vault protein (MVP), which consists of multiple subunits in a hollow barrel-like structure that functions in nucleo-cytoplasmic transport (224, 240). It has been proposed that MVP/LRP may act by transporting antitumor agents away from their subcellular targets, and supporting results have been published [for review, see ref. (183)]. However, it was reported that embryonic stem cells and bone marrow cells derived from murine MVP/LRP-knockout animals showed no difference in sensitivity to a wide spectrum of cytotoxic agents (182).

III. Redox Regulation of Multidrug-Resistance Transporters: Conformational Changes of the Transporters

The conformation of multiple membrane-spanning proteins is maintained by multiple parameters, including hydrogen bonds, hydrophobic effects, ion pairs, charge interactions, weak Van der Waal force, and intra- and intermolecular cysteine linkages. Several ABC transporters contain redox-sensitive amino acid residues such as cysteine (Cys). These Cys residues are subject to intramolecular disulfide formation, which is required for the maintenance of proper protein folding for their transporter's function. The eukaryotic machinery for controlling protein folding involving disulfide bond formation is carried out mainly by

protein disulfide isomerase (PDI), which occurs as both oxidized and reduced forms (Fig. 2). Oxidized PDI acts as a disulfide donor in the oxidative protein folding of reduced protein. After the oxidation of a nascent protein, PDI is in the reduced state, which is reoxidized by a cascade consisting of endoplasmic reticulum oxidoreductin 1 (Ero1), its cofactor flavin adenine dinucleotide (FAD), and O₂. The consumption of O₂ as the terminal electron acceptor leads to oxidative stress through the production of ROS, which up-regulate the production of GSH by upregulation of the expression of γ -glutamylcysteine synthetase (γ -GCS), the rate-limiting enzyme for the biosynthesis of GSH (see later). ROS also oxidizes GSH to GSSG, which is a substrate of MRP1-mediated transport (103).

The ratio between GSH and GSSG in cytosol is ~100:1, but in the endoplasmic reticulum (ER), it is ~3:1 (103). The maintenance of a sufficiently oxidizing environment in the ER is to compensate for disulfide formation. However, it is also known that Ero1 and PDI can drive the oxidation of protein folding, even in the reduced environment in which GSH is abundant. It is likely that Ero1- and PDI-mediated oxidative protein folding may gradually tip the equilibrium in favor of the formation of GSSG, whereas GSH-mediated reductive processes may feed back in maintenance of redox equilibrium. This dynamic redox homeostatic-regulation mechanism controlled by the coupled Ero1-PDI and GSH-GSSH systems may explain how ER supports rapid disulfide formation while it reserves the capacity to correct improper protein folding (262) (Fig. 2).

PDI contains two thioredoxin-like domains, each of which contains an active-site CXXC. Mutation in one of the active sites is sufficient to effect the folding of its target protein (98). Likewise, Ero1 has five known disulfide bonds, and two of them (Cys100-Cys105 and Cys 352-Cys355) are essential for the enzymatic activity *in vivo*. However, mutations in the noncatalytic cysteine pairs (Cys90-Cys-349 and Cys150-Cys295) affect Ero1 activity in a redox-dependent manner. When these cysteines are in reduced form, Ero1 is catalytically active; when they are in the oxidized form, Ero1 is inactive. These results demonstrate the importance of a redox environment in the regulation of the protein conformation of Ero1, which in turn regulates the global protein-folding machinery (236).

In addition to its function as a redox catalyst, PDI also functions as a chaperone by retaining proteins in the ER, thereby circumventing their protein degradation by the ubiquitin-proteasome pathway (83). Deregulation of these control mechanisms leads to the accumulation of unfolded protein in the ER; as a consequence, cells activate the intracellular unfolded protein-signaling pathway that triggers upregulation of a whole host of ER-stress proteins to overcome the stress. Perturbation of the capacity of this regulation, leading to excess production of disulfide bonds or misfolded mutant proteins, would ultimately lead to cell death.

The BCRP (ABCG2) protein contains 11 Cys residues. Three of them (Cys592, Cys 603, and Cys608) are located in the extracellular face between TM5 and TM6 (93, 117, 270). Cys592 and Cys608 are important for protein stability by forming intramolecular disulfide bonds. Mutations at these two Cys residues disrupt intramolecular disulfide linkage, resulting in protein misfolding and protein degradation, and

FIG. 2. Schematic model showing the regulation mechanism of oxidative protein folding in ER. Formation of disulfide bonds in the ER is driven by the Ero1, FAD, and PDI cascades. The reaction uses molecular O_2 as an electron acceptor that leads to the generation of ROS. PDI then carries out an isomerization reaction to produce proper protein folding. Reduced GSH may participate in the reduction of disulfide, resulting in the production of oxidized GSSG. Misfolded protein may be targeted to proteasome for protein degradation through ubiquitination. PDI and Ero1 are by themselves regulated by redox homeostasis. Formation of proper disulfide linkage by PDI leads to protein stabilization.

thereby increasing drug sensitivity because of the accumulation of the drugs (93, 117, 270).

Cys603 is involved in intermolecular disulfide bridge formation, resulting in dimerization of ABCG2. Mutation at this amino acid residue prevents the formation of homodimerization (270). Dimerization apparently does not require any amino acids other than those between TM5 and TM6. A recent study demonstrated that expressing a truncated BCRP consisting of TM5-loop-TM6 alone in cultured cells can oligomerize up to the dodecamer (93, 277). However, functional analyses revealed that mutation at Cys603 does not alter the transport activity of SN-38 and mitoxantrone by BCRP, although it has been generally perceived that monomeric ABCG2 represents a half-molecule of a functional ABC transporter. Recent study demonstrated that Cys284, Cys374, and Cys438 are potential sites for intramolecular disulfide bond formation and are required for the function of ABCG2 (158).

Intermolecular interactions involving critical Cys residues also occur in MRP family. As alluded to in Fig. 1, MRP1-3, 6, and 7 contain one extra MSD₀ at the N-terminus of the molecule. MSD₀ has been identified to be important for the dimerization of MRP1 (284). Dimerization of MRP1 is disrupted in the presence of dithiothreitol, suggesting that formation of disulfide linkage is mediated through the Cys residues. Yang *et al.* (283) investigated the roles of the two Cys residues (Cys7 and Cys32) located within the first 33 amino acids from the N-terminus of MRP1. These Cys residues are conserved among MRP1, 2, 3, 6, and 7 members. These investigators demonstrated that mutation at Cys7 drastically reduced LTC₄ transport activities, whereas mutation at Cys32 did not (284). Mutations at Cys7 caused conformational changes and prevented dimerization in truncated MRP1 in co-transfection assay (283). It is, therefore, likely that this Cys residue may be involved in the dimerization of MRP1. As for Pgp1, whether functional Pgp requires the formation of the homodimer *in vivo* remains controversial (32). Currently, >15 PDI-like proteins are known in the family (67). It is not known which PDI-like protein is involved in the maintenance of protein foldings for these ABC transporters.

IV. Redox Regulation of Multidrug-Resistance Transporter Activity

Several members in the MRP family require GSH for the transport activities. GSH is the most abundant physiologic antioxidant, underscoring the roles of redox regulation of multidrug resistance mediated by this group of ABC transporters. The first identified endogenous substrate of MRP1 was LTC₄ (113, 148, 184), which is a GSH conjugate immunomediator, consistent with the idea that MRP1 functions as a GS-X pump (108) (Fig. 3). The role of GSH in MRP1-mediated drug sensitivity in cultured cells was demonstrated: drug resistance in MRP1-overproducing cells could be par-

FIG. 3. Leukotriene biosynthesis and transport by the MRP1/GS-X pump. Leukotriene C₄ (LTC₄) is a GSH conjugate of LTA₄, which is a metabolite of arachidonic acid by lipooxygenase through the intermediate hydroperoxyeicosatetraenoic acid (HPETE). Arachidonic acid is also metabolized by cyclooxygenases 1 and 2 (COX1, COX2) to prostaglandins.

tially reversed by exposing the cells to buthionine sulfoximine (BSO), an inhibitor of GSH synthesis. The effect of BSO on drug resistance was associated with decreased GSH levels and increased intracellular accumulation of daunorubicin owing to inhibition of the enhanced drug efflux. Increased GSH levels in BSO-treated cells by exposing cells in GSH ethyl ester restored the accumulation deficit of doxorubicin (268), demonstrating the critical role of GSH in the MRP1-mediated transport activity.

MRP1 also transports GSSG, the oxidized form of GSH, with relatively higher affinity than does GSH. Thus, MRP1 can be considered a regulator of GSH–GSSG homeostasis and its associated redox maintenance. Several lines of evidence suggest that the initial event in GSH-dependent MRP1-mediated drug transport involves the interaction between GSH and MRP1. GSH is a tripeptide consisting of Glu–Cys–Gly. Lesie *et al.* (151) investigated the GSH-binding domain of MRP1 by using a variety of amino acid substitutions in the tripeptide and concluded that, although other factors are contributory to the overall interactions, the molecular volume of the tripeptide is important for supporting MRP1 transport activity. Substituting the γ -Glu residues with Gly, β -Asp, and α -Glu resulted in the complete loss of transport stimulation of MRP-mediated transport using estrone 3-sulfate as a substrate; whereas substituting the internal Cys residue had no effect. These observations suggest a stereospecificity of GSH in supporting the MRP transporter. It has been reported that several short-chain GSH derivatives can stimulate MRP1-mediated vincristine uptake in a membrane vesical transport assay, suggesting that change in redox state and glutathionation of substrate is not involved (162).

By using the radioactively labeled photoactivatable GSH derivative, azidophenacyl-³⁵S-labeled GSH, which can functionally substitute for GSH, in an MRP1-mediated substrate (estrone 3-sulfate) transport assay, Qian *et al.* (203) found that the GSH directly interacts with two sites located at the N- and C-terminal halves of MRP1. This raises possibilities as to whether GSH functions as a co-transporter or a co-factor that stimulates the transport of the others. The co-transporter mechanism is based on the findings that transport of substrates requires GSH and that substrates can also increase the transport of GSH. Support of the co-transporter model can be found in that the MRP1-mediated transport of vincristine (162) and daunorubicin (DNR) (162, 210) in an isolated membrane vesicle supplemented the physical concentration of GSH. Moreover, the MRP1-mediated efflux of daunorubicin parallels that of GSH with a 1:1 stoichiometry when drug transport is saturated (219), supporting the earlier findings with respect to GSH and vincristine transports (147, 162). However, such reciprocal stimulation of transport was not found in the transport of nitrosamine metabolite, NNAL-O-glucuronide (152). Likewise, conjugated estrogen, estrone 3-sulfate, could be efficiently transported only in the presence of GSH, but no reciprocal increase was found in MRP1-mediated GSH transport (166). The co-transport model is even more complicated when inhibitors to MRP1-mediated efflux were used. Salerno *et al.* (220) reported that verapamil inhibits MRP1-mediated efflux of DNR, whereas GSH efflux is increased. MK571 inhibits the efflux of both DNR and GSH. These observations led these investigators to propose a model in which two interactive modules, one for the substrate and the other for GSH, worked in concert for the MRP-mediated transport.

One possible model proposed for the co-factor mechanism of GSH in MRP1-mediated drug transport is that the allosteric effect induced by GSH may lead to conformational changes in MRP1, rendering it more accessible to substrate binding. Induction of MRP1 conformational changes by GSH binding is supported by the results of a study using a limited tryptic-digestion approach (209). The investigators observed that GSH inhibited the tryptic digestion of the Lo region, which links MSD₀ and MSD1 of MRP1 in purified membrane vesicle (Fig. 1). By using reconstituted lipid vesicles containing an inside-out MRP1 configuration, Manciu *et al.* (166) showed that GSH binding induces a conformational change in MRP1 that affects the structural organization of the cytosolic domains, resulting in enhanced ATP binding or hydrolysis or both. Despite the intensive investigations, however, the detailed mechanisms underlying how the conformational changes led to the enhancement of MRP1-mediated drug transport remain to be learned. Very little information is available regarding the structural requirements in the substrates that are required for GSH to function as a co-factor for MRP1 transport (53). Moreover, it is unknown why some members of the MRP family require GSH as a co-factor, whereas others do not. All these issues require further investigations.

V. Redox Regulation of Multidrug-Resistance Transporter Gene Expression

A. MDR/Pgp family

Because the level of *MDR1* gene expression is frequently upregulated in human malignancies, understanding the up-regulation mechanisms is important for designing strategies to circumvent the development of multidrug resistance in cancer chemotherapy. Nevertheless, most of our understanding of *MDR1* regulation mechanisms is from cultured cell studies. Multiple layers of regulation of *MDR1* gene expression have been demonstrated, including transcriptional, posttranslational, translational, and epigenetic levels. Moreover, the acquisition of multidrug resistance can be caused by gene amplification. These various layers of gene expression–regulation mechanisms are discussed.

1. Transcriptional regulation. Like many other RNA polymerase II-transcribed genes, *MDR1* promoter contains many transcription factor-binding sites (*e.g.*, GC-boxes, CCAAT-, CAGGAACA-, and GCGTGGGCT- elements, which interact with Sp1, NF-Y, ets-1, and Egr transcription factors, respectively). *MDR1* promoter (and most of the MRP family members as well) lacks the TATA box. These transcriptional factors contribute to the bulk of the basal transcriptional regulation. Moreover, *MDR1* expression can be induced by various stress conditions, including tumor promoter, UV and ionizing radiation, carcinogens, hypoxia, and chemotherapeutic agents. These are mostly stress-inducing agents that produce redox imbalance. Thus, various redox-induced signalings play important roles in transcriptional regulation of *MDR1* expression. Here are some examples:

Carcinogens: Early investigations of the effects of carcinogens on *mdr* gene expression were focused on hepatocellular carcinoma (HCC) in rodents. HCC in the rats or mice can be induced by many different inducers (133). Teeter *et al.* (254) reported that the expression of the murine *mdr1a*, a paralogue

of the human *MDR1*, was overexpressed in four different liver-tumor models, including chemical induction with diethylnitrosamine (DEN), dimethylhydrazine, transgenic mice bearing hepatitis B viral (HBV) large-envelope polypeptide, and even spontaneous tumors. Interestingly, in rats, up-regulation of *mdr1b* (another human *MDR1* paralogue) was induced by the hepatocarcinogen, 2-acetylaminofluorene (2-AAF) (133, 255).

Further study in cultured cells demonstrated that a nuclear factor-kappa B (NF- κ B) site (−167 to −158 bp from the transcription start site) on the rat *mdr1b* promoter was required for the induction of *mdr1b* expression by 2-AAF. Overexpression of antisense p65 or I κ B β , an inhibitor of NF- κ B, partially abolished the induction. 2-AAF treatment led to the increase of intracellular ROS, which causes activation of I κ B kinase (IKK), degradation of I κ B β (but not I κ B α), and increase in NF- κ B DNA-binding activity. The antioxidant N-acetylcysteine (NAC) inhibited the induction of *mdr1b* expression by 2-AAF. Overproduction of GSH by transfection with expressing recombinant encoding its rate-limiting enzyme, γ -GCS large subunit (γ -GCSH), blocked the activation of IKK kinase complex and NF- κ B DNA binding. These results strongly suggested that 2-AAF upregulates *mdr1b* through the redox signaling that activates IKK through degradation of I κ B β , and subsequent activation of NF- κ B (61) (Fig. 4).

Although the promoter sequences of human *MDR1* and rat *mdr1b* are quite distinct, 2-AAF also induces *MDR1* expression in human hepatic cells through an NF- κ B DNA sequence located at −6092 bp. Treating hepatoma cells with 2-AAF activates phosphoinositide 3-kinase (PI3K) and its downstream effectors Rac1 and NADPH oxidase, a cellular source of ROS generator (Fig. 5). Transient transfection assays demonstrated that constitutively activated PI3K and Rac1 enhanced the activation of the *MDR1* promoter by 2-AAF. Treatment of hepatoma cells with 2-AAF also activates another PI3K downstream effector protein kinase B (Akt). Transfection of recombinant encoding a dominantly acti-

vated Akt also enhanced the activation of *MDR1* promoter activation by 2-AAF. These results demonstrated that 2-AAF upregulated *MDR1* expression is mediated by the multiple effectors of the PI3K/ROS signaling pathway (137).

Hepatocarcinogen DEN, which promotes hepatocarcinogenesis with the accompanying *mdr1a* expression in mice, is also through the NF- κ B activating pathway (186). The upstream signaling that activates NF- κ B induced by DEN is Toll-like receptor (TLR)-MyD88 in the Kupffer cells. DEN causes 100% HCC in male mice but only 10 to 30% in female mice. The NF- κ B signal not only upregulates *mdr1a*, which may contribute to intrinsic drug resistance (see later), but also enhances the production of various cytokines that promote hepatic proliferation. One of these cytokines is interleukin (IL)-6, which is responsible for the gender difference in DEN-associated HCC incidence (186) (Fig. 4).

The results described underscore the importance of the NF- κ B transcription factor in the carcinogen-induced *MDR1* gene activation. NF- κ B represents a group of structurally related and evolutionarily conserved proteins, with five members in mammals: Rel (c-Rel), RelA (p65), RelB, NF- κ B1 (p50 and its precursor p105), and NF- κ B2 (p52 and its precursor p100) (75). The classic NF- κ B activating pathway is activated by a variety of cytotoxic compounds as well as many innate and adaptive immunity mediators such as TNF- α , IL-1 β , and Toll-like receptor. The elicited initial signalings all converge in the activation of the IKK complex by phosphorylation of its component IKK β , which consists of scaffold protein NEMO (also called IKK γ), IKK α , and IKK β kinases. Once activated, the IKK complex in turn phosphorylates inhibitory protein kappa B (I κ B α on Ser32 and Ser36, which is then ubiquitinated and degraded via the proteasome pathway. This releases NF- κ B p65/p50, which translocates into the nucleus and activates its target genes. The nonconventional pathway is IKK α dependent and IKK β independent but involves the phosphorylation and processing of p100, generating p52:RelB heterodimers, which then translocate into the nucleus and activate transcription (Fig. 4). Both path-

FIG. 4. NF- κ B signaling and *MDR* gene expression. Activation of *mdr1b* expression by the carcinogens 2-AAF and DEN is shown in two different pathways but converges into NF- κ B signaling. Induction by 2-AAF is through the activation of PI3K signaling, whereas that by DEN occurs through the Toll-like receptor (TLR) signaling pathway. Membrane TLRs recognize external signals. When activated, the majority of TLRs induce activation of NF- κ B and cytokine production in a MyD88-mediated manner. Also shown is the nonconventional transduction pathway induced by CD40 and EBV.

FIG. 5. Activation of NADPH oxidase and the generation of ROS. NADPH oxidase consists of six subunits. Under noninduced conditions, two of the subunits (gp91 and p22) are membrane bound, and the other four (p67, p47, p40, and Rac) are in cytoplasm. Activation is initiated by Rac1 and p47 phosphorylations and brought all the subunits to the membrane, where it generates superoxide, which is metabolized by superoxide dismutase (SOD) into water.

ways ultimately lead to the transcription of distinct sets of target genes, mediating different biologic functions. Apparently, activation of MDR1 expression by 2-AAF and DEN treatments is mediated by the classic IKK β -dependent pathway.

The Epstein-Barr virus (EBV) is a ubiquitous human herpesvirus and frequently is associated with the development of different epithelial malignancies. Breast cancer cells infected with EBV conferred resistance to paclitaxel with overexpression of MDR1 (7). Although the mechanism of MDR1 upregulation by EBV infection has not been investigated, it has been demonstrated that EVB can elicit activation of NF- κ B signaling through the nonconventional transduction pathway (165) (Fig. 4). It is likely that EBV-induced MDR1 expression in breast cancer cells is involved with the nonconventional NF- κ B signaling, but this remains to be investigated.

Antitumor agents: Induction of MDR1 expression by anti-tumor agents is likely to be an important contributor to the acquired multidrug resistance in cancer chemotherapy. Many studies have shown that MDR1 gene expression can be transiently induced by cancer chemotherapeutics, and in some studies, transcriptional regulation is involved (see review in 186 and references therein). Of particular importance is that such transient upregulation of MDR1 expression was also seen in chemotherapy. In one acute myeloid leukemia (AML) patient, the Pgp1 level was upregulated *in vivo* at 4 and 16 h after the standard treatment with daunomycin/Arac. Acute induction of MDR1 gene expression in four of five patients with unresectable sarcoma pulmonary metastases who underwent isolated single-lung perfusion with doxorubicin was seen 50 min after the administration of doxorubicin (2). The mechanisms of upregulation in these patients were not studied.

The expression of MDR1 in tumors has been evaluated in many clinical investigations in leukemia and in solid tumors. Elevated expression of MDR1 after chemotherapy has been observed in AML, breast cancer, ovarian cancer, and cervi-

cal cancer, suggesting the induction of MDR1 expression by chemotherapeutic treatments. The mechanism by which MDR1 expression levels were elevated in the patients was not determined. Other studies, however, showed no changes in MDR1 expression levels after chemotherapy [for review, see ref. (249)].

Hypoxia: Advanced local tumors often contain areas where oxygen availability is reduced, because of the poor supply of functional blood vessels. The expression of hundreds of genes in cancer cells is altered under hypoxic conditions (234). MDR1 expression has been shown to be induced by hypoxia. A conserved hypoxic response is mediated by the transcription factor complex known as hypoxia-inducible factor (HIF), which consists of one constitutively expressed HIF-1 β (also known as ARNT) and one of the three HIF-1 α forms (HIF-1 α , HIF-2 α , and HIF-3 α). HIF-1 α is very unstable under normoxic conditions, whereas it is stabilized under hypoxic conditions. Oxygen regulation of HIF-1 α levels lies in the two proline residues of the HIF-1 α oxygen-dependent domain, which are hydroxylated by prolyl hydroxylase-domain protein (PHD, also called EglN). Hydroxylated HIF-1 α is recognized by the von Hippel-Lindau (pVHL) and is targeted for ubiquitination and subsequent proteasomal degradation (99).

Recent results indicate that the stability and expression levels of HIF transcription factors can be regulated by ROS under nonhypoxic and hypoxic conditions [for reviews, see ref. (43, 201, 252)]. Under normoxia, HIF-1 α is stabilized by oxidative stress induced by H₂O₂, and antioxidants markedly attenuate HIF-1 α protein accumulation, perhaps by the inactivation of the PHD (201). However, the regulation mechanisms of HIF-1 α by ROS under hypoxic conditions are complex. Several groups reported that ROS levels are elevated in hypoxia, whereas others reported that ROS levels are decreased in hypoxia [see ref. (252) and references therein]. This discrepancy may lie in basal cell metabolism and the degree and duration of hypoxia experienced. Regardless, several recent studies demonstrated that mito-

chondria function as oxygen sensors and signal hypoxia by releasing ROS. Dysfunction of the mitochondrial electron-transport chain results in impaired hypoxia-induced ROS that is required for hypoxia-induced HIF- α stability (38, 85, 116, 169), through inactivation of PHD by the bound iron (Fig. 6). In addition to VHL-dependent regulation, the PI3K/Akt or protein kinase B (PKB) signaling-transduction cascade has been implicated in the regulation of HIF-1 α (21, 79, 261). It is important to note that PI3K is also involved in the regulation of *MDR1* expression (137).

Induction of *MDR1* by hypoxia is mediated by the binding of HIF to the hypoxia-response element located at the promoter of *MDR1* gene (55, 157). In addition, c-Jun NH₂-terminal kinase (JNK) is also known to affect hypoxia-induced *MDR1* expression (55, 157). Further investigation revealed that the JNK pathway functions as a negative regulator of *MDR1* expression under normoxia, whereas JNK-induced *MDR1* activation under hypoxic conditions is dependent on increased HIF1 binding to the hypoxia-response element where transcription co-activator p300/CBP also participates (157).

2. Posttranscriptional regulation. Translational control of *MDR1* gene expression has recently been described in K562 myelogenous leukemic cells treated with several different antitumor agents. The half-life of *MDR1* mRNA from naïve K562 cells is ~1 h, whereas that from doxorubicin- and colchicine-resistant cells is 12–16 h (279), suggesting that induction of the steady-state *MDR1* mRNA levels was due to enhanced mRNA stability. Interestingly, this stabilized mRNA was not associated with translating polyribosomes and did not direct Pgp synthesis. However, selection for drug resistance by continuing exposure to the drug led to release of the translational block, *MDR1* mRNA translation, and Pgp expression (279). Translational blockage was apparently due to the presence of a double-stranded configuration with loops located at the 5'-UTR of *MDR1* mRNA. When this structure was inserted into a luciferase reporter construct, on transfection of the reporter construct into cultured cells, this

structure downregulated the translation efficiency of the reporter under the treatment with a cytotoxic drug. This double-stranded structure affects translation efficiency initiated by eIF4E. This translation repression can be relieved by overexpression of eIF4E (204). These observations demonstrate the translational control of *MDR1* protein expression by cytotoxic assaults.

3. Epigenetic regulation. Two types of epigenetic regulation have been discovered in *MDR1* gene regulation. The first one is DNA methylation. The promoter region of *MDR1* is highly GC rich and contains many CpG islands that are targets of DNA methylation-related transcriptional silencing. Several studies have demonstrated that the methylation status in the *MDR1* promoter is correlated with the transcriptional activity of *MDR1* gene (12, 13). The methylation reaction is catalyzed by DNA methyltransferases (DNMTs) using S-adenosylmethionine (SAM) as methyl donor to the 5 position of the pyrimidine ring of cytosine within CpG dinucleotides in genomic DNA, resulting in the production of 5-methyl-cytosine and S-adenosylhomocysteine (Fig. 7). Two classes of DNMTs are present in mammalian cells. DNMT1 belongs to the first class and is associated with a replication fork and methylates CpG in the newly synthesized DNA strand. DNMT3 belongs to the second class required for *de novo* methylation during embryonic development. DNMT1 is essential for the maintenance of DNA-methylation patterns in proliferating cells. SAM is the first metabolite of the methionine cycle catalyzed by S-adenosylmethionine synthetase, also known as methionine adenosyltransferase (MAT). The methionine cycle is the major source for cysteine, a precursor of GSH in the transsulfuration pathway. However, intracellular GSH level plays an important role in the maintenance of methylated DNA. Depleting GSH by using the hepatotoxin bromobenzene resulted in reduced intracellular methionine pools and genome-wide DNA hypomethylation (150). Another target in the methionine cycle that is subject to redox regulation is MAT, which exists in three forms in mammalian cells, MAT1, MATII, and MATIII.

FIG. 6. Redox-regulated HIF-mediated signaling pathways in multidrug-resistance gene expression and other physiologic processes. In the presence of oxygen, the α subunit of the heterodimeric transcription factor HIF is hydroxylated on prolyseresidues by PHD. Hydroxylated HIF is subjected to polyubiquitination by pVHL for degradation. PHD requires oxygen and Fe²⁺. Hypoxia inhibits proly hydroxylation, resulting in stabilization of HIF, and through increased ROS, which oxidize PHD-bound iron. Mitochondrial complexes I to IV are required for hypoxia-mediated ROS. Stabilized HIF elicits multiple physiologic processes, including enhanced glycolysis (the Warburg effect), oncogenesis, angiogenesis, cell growth, and regulation of multidrug-resistance gene expression.

FIG. 7. Schematic diagram showing the effects of redox conditions on the metabolism of the methionine cycle and DNA methylation. A transsulfuration pathway is involved the production of cysteine, which is the substrate for the production of glutathione. SAM, S-adenosylmethionine; SAH, S-adenosylhomocysteine; MAT, S-adenosylmethionine synthetase; γ -GCS, γ -glutamylcysteine synthetase; gly, glycine; glu, glutamine; cys, cysteine.

MAT I functions as a homotetramer. MAT II is the predominant form of SAM synthetase and exists in a multimeric complex. MAT III is a homodimer (86). The activities of these MATs are profoundly influenced by redox conditions, through the maintenance of homotetrameric conformation.

The second type of epigenetic regulation is through histone modification at the *MDR1* promoter chromatin. The gene-silencing effects of methylated DNA are contributed mainly by the binding of the repressor protein, methyl-CpG-binding protein-2 (MeCp2), which has been demonstrated to localize at hypermethylated *MDR1* chromatin. Demethylation of the *MDR1* promoter by 5-azacytidine treatment was associated with release of MeCp2 from *MDR1* promoter and its transcriptional activation. MeCp2 silences transcription by recruiting the interacting co-repressor proteins, SWI independent protein 3 (mSin3), histone deacetylase 1 (HDAC1), and HDAC2. Oxidative damage to CpG islands inhibits binding of the MeCp2 to the lesions (264). Moreover, treatment of cells with the HDAC inhibitors trichostatin A or sodium butyrate leads to the activation of hyperacetylation of *MDR1* proximal-promoter histone and activation of

MDR1 transcription (114). Increased expression of *MDR1* and Pgp was observed in the peripheral blood mononuclear cells (PBMCs) of patients enrolled in a phase I or II trial with depsipeptide, a histone deacetylase inhibitor. Increased levels of histone H3 acetylation were found in PBMCs and circulating tumor cells obtained from patients receiving depsipeptide. Because depsipeptide is a substrate of Pgp, these results suggest that upregulation of *MDR1* induces its mechanism of resistance (216). Taken together, these observations underscore the importance of redox in epigenetic regulation of *MDR1* expression in the clinical setting.

B. γ -Glutamylcysteine synthetase (γ -GCS)

γ -GCS is not a multidrug-resistance gene, but its expression is closely associated with that of *MRP1*. As alluded to earlier, the transport activities of several members of the MRP family are regulated by GSH availability, and γ -GCS is the rate-limiting enzyme for the *de novo* biosynthesis of GSH. Co-regulation of γ -GCS and *MRP1* would facilitate the efflux activity (Fig. 8). Indeed, as is discussed later, we found that a number of agents that induce the expression of γ -GCS

FIG. 8. Roles of GSH in MRP-mediated drug transport. *De novo* biosynthesis of GSH is carried out by γ -GCS, which conjugates glutamine (Glu) and cysteine (Cys) followed by GSH synthetase, by using glycine (Gly) as a substrate. GSH can be oxidized into GSSG by GSH peroxidase. GSSG is a substrate of the MRP/GS-X pump. GSH either forms a conjugate or functions as a cofactor for MRP1/GS-X pump-mediated transport. Thus, GSH by itself can be transported by the MRP1/GS-X efflux pump, albeit at a reduced rate, as compared with that of GSSG. The importance of GSH in MRP1/GS-X-mediated transport is reflected by the frequent co-upregulation of γ -GCS and *MRP1* by extracellular influences.

can also induce the expression of *MRP1*. The mammalian γ -GCS is a heterodimer consisting of one 73-kDa heavy or catalytic subunit (γ -GCS_h) and one 28-kDa light (regulatory) subunit (γ -GCS_l). Hereditary γ -GCS_h deficiency is associated with anemia, jaundice, and neurologic abnormalities (87, 213), whereas hepatic ablation of γ -GCS_h results in steatosis with mitochondrial injury and hepatic failure, demonstration of the essential roles of GSH in the liver physiology (48). Here I present the mechanisms underlying redox regulation of γ -GCS_h, but similar mechanisms may be applicable to the regulation of γ -GCS_l.

1. Transcriptional regulation. Our laboratory previously demonstrated that expression of γ -GCS_h can be induced by a number of cytotoxic challenges, including antitumor agents (77, 109), heavy metals (109), carcinogens (282), and prooxidants (106, 282). All these inducers, at the concentrations used, exert various degrees of oxidative stresses. Furthermore, enhanced expression of γ -GCS_h mRNA was found in colorectal cancers, which are associated with inflammation-associated oxidative stress (136, 251). These observations strongly suggested that the GSH/ γ -GCS system is a molecular sensor of oxidative stress conditions. Whereas elevated expression of γ -GCS_h catalyzes the enhanced expression of GSH, we observed increased GSH levels feed back and downregulate the steady-state γ -GCS_h mRNA level (282). This feedback mechanism underscores the importance of γ -GCS_h as a major redox regulator.

Transcriptional regulation of γ -GCS_h expression is mediated by an antioxidant response element (ARE) that contains a consensus sequence 5'-TGAGTCA, which interacts with NF-E2-related factor (Nrf2). In *Nrf2*(-/-) animals, expression levels of γ -GCS_h mRNA and γ -GCS_l mRNA are only 58% and 65%, respectively, of the level in wild-type controls (42), demonstrating the role of Nrf2 in the regulation of steady-state levels of γ -GCS_h and γ -GCS_l.

The transcription factor Nrf2 is a member of the "cap 'n' collar" family of basic leucine zipper transcription factors. Mechanisms by which Nrf2 mediates upregulation of antioxidant enzyme genes have been the subjects of intensive study in recent years (56, 290). Nrf2 binds to ARE and regulates ARE-mediated antioxidant enzyme genes both at the basal levels and in conditions in which upregulation is stimulated by a variety of antioxidants. Nrf2 is an unstable protein, the stability of which can be enhanced by the treatment with proteasome inhibitor lactacystin. This treatment resulted in increased steady-state levels of γ -GCS_h mRNA levels (231). Under nonstress conditions, Nrf2 is bound to Kelch-like ECH-associated protein (Keap1), which is a cytosolic actin-associated protein (112). Keap1 functions as a substrate adaptor for a Cullin-dependent E3 ubiquitin ligase complex and targets Nrf2 for ubiquitination after proteasomal degradation (Fig. 9). Human Keap1 contains 27 cysteines of a total of 624 amino acids. Cys273 and Cys288 are essential for the repressive activity of Keap1 under nonstress conditions (127). Under oxidative stress conditions, Keap1 undergoes a Cys151-mediated posttranslational modification, resulting in a conformational change of the Keap-Cullin3 (Cul3)-Rbx1 E3 ubiquitin ligase. This conformational change suppresses the ubiquitin ligase activity, thereby inhibiting Nrf2 degradation (238) and allowing Nrf2 to translocate into the nucleus and heterodimerize with the small Maf proteins, MafK or MafG

FIG. 9. Nrf2 and transcriptional regulation of γ -GCS_h expression. Under nonstress conditions, Nrf2 is complexed with Keap1 and targeted to Cul3-mediated ubiquitination and protein degradation. Under oxidative-stress conditions, such a degradation pathway is inhibited, and Nrf2 accumulates. Nrf2 then translocates into the nucleus, where it complexes with MafK, which transactivates target genes. Oxidative stress also induces Nrf2 phosphorylation. γ -GCS_h is a target gene of Nrf2. Overexpression of γ -GCS_h leads to elevated biosynthesis of GSH, which in turn suppresses oxidative stress.

co-activator, the basic leucine zipper transcription factor of the Maf (proto)-oncogene family (62). Together they bind to ARE and transactivate γ -GCS_h expression. Upregulation of γ -GCS_h expression results in feedback to suppress the Nrf2-Keap1 signaling (Fig. 9). Similar mechanisms are involved in the regulation of the expression of many so-called phase II detoxifying enzymes [e.g., quinone oxidoreductase 1, glutathione S-transferase (GSTA1), and heme oxygenase 1 (188)], which covalently modify xenobiotics for elimination by transport.

Additional pathways have been described to account for induced Nrf2-mediated transcriptional activation.

1. Oxidative stress activates several protein kinases including PKC (28, 101), p38 mitogen-activated protein kinase (287, 294) and PI-3 kinase (144), which phosphorylate Nrf2 and enhance its transactivating signaling of ARE containing genes.
2. Oxidative stress disrupts Keap1-Nrf2 interactions by modifying the two critical cysteine residues of Keap1, resulting in the release of Nrf2, which subsequently translocates into the nucleus (112) (Fig. 9).
3. An additional mode of regulation of Nrf2 is the subcellular localization of Keap1. Although the primary distribution of Keap1 is in the cytoplasm, it has been observed to accumulate in the nucleus in the presence of leptomycin B, an inhibitor of nuclear export signal. Keap1 does not contain a nuclear-localization signal amino acid sequence, but Nrf2 does. It is suggested that Keap1 may ride on Nrf2

and shuttle in and out of the nucleus. It has been suggested that under normal physiologic conditions, Nrf2 is the target for Keap1-induced proteasome-mediated degradation. Oxidative stress prevents Keap1 from targeting Nrf2 to proteasome degradation inside the nucleus, resulting in further nuclear accumulation of Nrf2 and transactivates ARE-mediated gene expression (187).

2. Posttranscriptional regulation. In addition to the transcriptional regulation of γ -GCSH expression mediated by the transcription factor Nrf2, oxidative stress can regulate gene expression posttranscriptionally. Posttranscriptional regulation of γ -GCSH expression was previously suggested by nuclear run-on assay (77). Further investigation demonstrated that oxidative stress-inducing agents (*e.g.*, sulindac, pyrrolidinedithiocarbamate, and *tert*-butylhydroquinone), induced γ -GCSH mRNA stabilization through the p38 MAP kinase pathways. p38 MAP kinase activates MAPKAPK2, which promotes the cytoplasmic translocation of mRNA-stabilizing factor HuR, a member of ELAV family of AU-rich binding RNA-binding protein, from the nucleus to cytoplasm and interacts with the AU-rich sequence located at the 3' untranslated region of γ -GCSH mRNA. The accumulated γ -GCSH mRNA produces elevated levels of GSH, which suppress oxidative stress and also feeds back to suppress γ -GCSH mRNA stabilization (242) (Fig. 10).

The posttranscriptional regulation mechanism of γ -GCSH mRNA levels may have clinical implications. It has long been thought that increased oxidative stress is associated with carcinogenesis, particularly in colon cancer (41). It was previously observed that γ -GCSH is frequently overexpressed in colon cancer (136, 251). Moreover, the development of colon cancer in experimental animals correlates with HuR content. Colon cancer cells overexpressing HuR produced significantly larger tumors than those arising from control cells, whereas those with reduced HuR levels through small in-

terference RNA or antisense HuR-based approaches developed significantly more slowly (163). Last, constitutively elevated p38 MAPK expression is frequently associated with cancer progression (63, 171, 173).

Activation of p38 MAP kinase signaling by oxidative stress can be traced to the upstream regulator, MAP kinase kinase (MKKK). At least one mechanism can account for the activation of MKKK by oxidative stress. It has been demonstrated that under normal physiologic conditions, the reduced form of thioredoxin is complexed with apoptosis signal-regulating kinase 1 (ASK1) (also known as MKKK 5) and inhibits ASK1 activity (105). With oxidative stress, thioredoxin is oxidized and dissociated from ASK1, which subsequently activates downstream signaling, by sequential phosphorylation of MKK3/6 and p38 MAPK (80) (Fig. 10). In addition, many antioxidative enzymes and molecular chaperons, including HPs72, glutaredoxin, and glutathione S-transferase, also inhibit the activation of ASK1 (170).

Another mechanism by which ROS activate MAPK pathways is by inactivating phosphatases, such as protein tyrosine phosphatase 1B and protein phosphatase C2 and C5 (123). Overexpression of GSTm1 has been reported to inhibit the oxidative stress-induced activation of p38 MAPK by binding to and inhibiting ASK1 (51). Dolado *et al.* (64) reported that p38 α -deficient cells derived from p38 α -/- mouse, when transformed by the activated HRasV12 oncogene, caused increased proliferation, increased number of foci in soft agar, ability to form colonies in soft agar, and decreased apoptosis (64). These effects could be rescued by ectopic expression of p38 MAPK. This observation suggests that p38 MAPK functions as a suppressor of tumor formation by HRas, which is known to cause increased ROS production. Dolado *et al.* (64) showed that the accumulated ROS in the HRas-transformed fibroblasts induce apoptosis, whereas the p38 α -deficient cells are resistant to the ROS-induced apoptosis. These observations suggest that the ability

FIG. 10. Posttranscriptional regulation of γ -GCSH mRNA stability by the MAP kinase pathway under oxidative-stress conditions. Oxidative stress activates MKK kinase, which phosphorylates its downstream mediators, MKK, MAPK, and MAPKAPK2, resulting in the translocation of mRNA stabilizing factor, HuR, from the nucleus into the cytoplasm. HuR binds to the 3'-UTR of γ -GCSH mRNA and stabilizes it from degradation. Increased γ -GCSH leads to elevation of an amount of GSH, which in turn suppresses oxidative stress.

of p38 MAPK to activate apoptosis in response to oncogene-induced ROS accumulation is important for the regulation of malignant transformation.

C. MRP family

As with γ -GCSH, our laboratory has demonstrated that expression of *MRP1* in cultured cells can be induced by a variety of cytotoxic agents, including prooxidants (155), heavy metals (109), carcinogens (282), antitumor agents, and nitric oxides (106). These observations raise an interesting scenario that mechanisms underlying induced expression of *MRP1* and γ -GCSH may be co-regulated. It should be pointed out that, although frequent simultaneous upregulation of *MRP1* and γ -GCSH has been observed under oxidative-stress conditions, the magnitude and time course of upregulation were not coordinated, depending on the cell lines used (p53 status) and types of inducers (155). This is also true for the induction of other members of MRP gene family. Some members (*MRP3* for example) are more sensitive to induction of certain peroxidants than are others (*MRP1*) (155).

As mentioned earlier, regulation of γ -GCSH gene expression by cytotoxic assaults is mediated at multiple levels, including transcriptional and posttranscriptional regulations. Whereas transcriptional regulation of γ -GCSH is mediated by Nrf2, which recognizes ARE in the promoter of γ -GCSH, no such element has yet been identified in the promoters of human *MRP1* and *MRP2* (122, 250). However, when Nrf2 was knocked down by siRNA, induction of *MRP2* and *BCRP*, but not *MRP1*, by *tert*-butylhydroquinone, in human hepatoma HepG2 cells was significantly suppressed (3). These results demonstrate that although expression of both *MRP1* and *MRP2* can be induced by oxidative stress, only *MRP2* expression is Nrf2 dependent.

The potential involvement of Nrf2 in the regulation of murine *mrp1*, *mrp2*, *mrp3*, and *mrp4* has been suggested, but the results are not consistent from different reports. Hayashi *et al.* (91) reported that the constitutive expression levels of murine *mrp1* mRNA were significantly lower in *Nrf2*(-/-) cells than in the wild-type cells. Induction levels of *mrp1* expression by diethyl maleate in *Nrf2*(-/-) cells were significantly reduced, suggesting a role of *Nrf2* in the regulation of murine *mrp1* by oxidative stress. An ARE-like sequence that responds to chemical-induced oxidative stress located at the mouse *mrp2* promoter has been identified. This ARE contains an Nrf2 binding site, and expression of Nrf2 upregulates *mrp2* expression (269). *Nrf2*-null mice are very sensitive to the acetaminophen (APAP)-induced hepatotoxicity, resulting in elevated expression of NADPH quinone oxidoreductase (Nqo1) and γ -GCSH. Treatment of *Nrf2*-null animals with APAP showed only moderate reduction of *mrp1* and *mrp2* proteins. In contrast, significant induction of *mrp3* and *mrp4* mRNA levels by APAP was seen in the wild-type animals but not in the *Nrf2*(-/-) mice, suggesting that Nrf2 is a more potent regulator for the upregulation of *mrp3* and *mrp4* by APAP than for the *mrp1* and *mrp2* in animal studies (4).

In addition to Nrf2, recent results suggested that *MRP1* and γ -GCSH are regulated by *N-myc*. The promoters of human *MRP1* and γ -GCSH contain multiple E-box sequences that are recognized by oncoprotein transcription factors *N-myc* and *C-myc*. In childhood neuroblastoma, high levels of

MRP1 expression correlate with overexpression of *N-myc*. Enforced expression of *N-myc* by using a tet-inducible expression system increased *MRP1* expression, resulting in increased drug resistance and enhanced *MRP1*-mediated drug efflux (168). Likewise, it has been demonstrated that γ -GCSH is one of the target genes of *c-Myc* (22). Oxidative stress induced by H₂O₂ treatment recruits *c-Myc* to the γ -GCSH promoter through ERK-dependent phosphorylation at Ser62 (22, 23). These studies may also explain the coordinated expression mechanism of γ -GCSH and *MRP1* by oxidative stress and also provide a clue as to how expression of *C-myc* may regulate intracellular ROS levels that contribute to genomic instability, cell-cycle regulation, and cell proliferation.

D. BCRP/ABCG2

The initial discovery that pheophorbide *a* is an endogenous substrate for *BCRP* revealed the importance of intracellular porphyrin/heme contents regulation by *BCRP* (115). The regulation of porphyrin and heme in the context of redox biochemistry is important for the following reasons: (a) The iron contained in heme serves as a source of electrons during electron transfer in redox biochemistry. Accumulation of heme within the cell ultimately leads to iron overload, resulting in the production of ROS by the Fenton reaction; and (b) Heme/porphyrin accumulation also leads to the collapse of mitochondrial function, the powerhouse for generation of ROS. This is particularly acute when cells are exposed under hypoxic conditions in which oxygen tension is low.

Biosynthesis of porphyrin/heme is initiated inside the mitochondrion with the formation of δ -aminolevulinic acid (dALA) from glycine and succinyl-CoA from the citric acid cycle (Fig. 11). Two molecules of dALA then form a porphobilinogen catalyzed by ALA porphobilinogen, which, after a few enzymatic reaction steps, leads to the formation of coproporphyrinogen III, all in the cytoplasmic compartment. Coproporphyrinogen III is transported into mitochondrion by the ABCB6 importer (129). After a few intermediate steps inside the mitochondrion, the main end product is protoporphyrin IX, which is combined with iron to form heme. Cellular levels of porphyrin and heme are regulated by the expression of ABCB6, but the elimination of porphyrins is carried out by *BCRP*/*ABCG2*. Degradation of heme uses the NADPH/NADP system and requires molecular O₂ with the formation of end-product bilirubin, which is then glucuronidated and eliminated by *MRP2* in the livers. Therefore, three ABC transporters are involved in the regulation of heme/porphyrin homeostasis, communicating between mitochondrial and cytoplasmic compartments that are tightly regulated by intracellular redox conditions.

The redox biochemistry contributed by porphyrins is their sensitivity to photodynamic excitation. Photoexcited porphyrins play an important role in the formation of singlet oxygen (¹O₂) by transferring energy to molecular oxygen, which at ambient temperature behaves as a triplet and is paramagnetic. ¹O₂ is a strong oxidant owing to its unpaired electrons with opposite spins, whereas the ground-state triplet oxygen has the same spins. ¹O₂ is an important source for the formation of ROS. Porphyrins-containing proteins play important roles in various physiologic processes, including oxygen transport and storage (hemoglobin), drug

FIG. 11. Metabolic pathways of heme/porphyrin biosynthesis and elimination by ABCG2 transporter. Biosynthesis of protoporphyrin and heme starts in mitochondria. After multiple steps of enzymatic reactions, as indicated. ABCB6 is involved in the import of coproporphyrinogen into the mitochondrion. Elimination of protoporphyrin IX involves ABCG2. Heme is metabolized to bilirubin, which is eliminated by ABCG2 in the liver. ALA, amino-levulinic acid.

metabolism (CYP450), mitochondrial respiration system (cytochrome *c* oxidase), *etc.* Porphyrins are inherited disorders resulting from the dysfunction of specific enzymes involved in heme biosynthesis (141).

To deal with the build-up of porphyrins, animal cells have developed detoxification mechanisms by increasing the expression of *ABCB6* and *BCRP*. However, mechanisms by which elevated porphyrins enhance the expression of *ABCB6* have not yet been elucidated. Expression of *BCRP* is regulated by hypoxia (107), which is mediated by HIF-1. An HIF-1 interacting *cis*-element is located at the *BCRP* promoter (at -116 to -112 nt) (128). Cells lacking HIF-1 were unable to upregulate *BCRP* expression. Because mitochondrial ROS has been implicated as a sensor for HIF-1 transcription factor, and because mitochondrial ROS also plays an important role in the regulation of porphyrin metabolism, these make mitochondrial physiology an integral partner in the overall regulation of the *BCRP* transporter.

Expression of *BCRP* is also under hormonal regulation. An estrogen receptor-binding element at -190 to -171 nt (66) and a peroxisome proliferator-activated receptor γ (PPAR γ)-responsive element (-3946 to -3796) (245) have been located. These *cis*-acting elements are involved in the regulation of *BCRP* by their respective ligands. Moreover, a recent study demonstrated that transcriptional regulation of *BCRP* expression in the drug-resistant variants is controlled by histone acetylation/deacetylation (258), demonstrating that epigenetic mechanisms also play a role in this regulation.

BCRP is normally localized in the plasmic membrane and intracellular compartment. Recent studies have shown that the PI3K/Akt signaling can affect the distribution of *BCRP* between the apical surface of the membrane and the cytoplasmic compartments. Takada *et al.* (247) demonstrated that an inhibitor to PI3K, wortmannin, causes translocation of *ABCG2* to the intracellular compartment in human LLC-PK1 cells. Redistribution of *ABCG2* was also observed in Akt-

dominant negative cells. Similar results were observed in hematopoietic stem cells, where *BCRP* is enriched in the side population (SP) cells. Bone marrow from Akt-null mice exhibited a reduced SP fraction, and lentivirus-mediated overexpression of Akt1 in bone marrow greatly increased the SP fraction (179). These results demonstrate that the PI3K/Akt signaling pathway modulates intracellular distribution of *BCRP*; however, the physiologic implication of such redistribution is yet to be defined.

VI. Redox Regulation of Multidrug-Resistance Transporters: Gene Amplification

Amplification of *mdr1* gene copy number was discovered in multidrug-resistant cell lines overexpressing the encoded Pgp1 protein soon after the cloning of the *MDR1* cDNA, and was considered one of the major mechanisms for the regulation of drug resistance (26, 174, 227, 253). Like in many other prior drug-resistant variants, amplified DNA can be either extrachromosomally located, known as double minutes (DM), or chromosomally borne at segments manifested as abnormal banding regions (ABRs). For reasons yet to be determined, amplified *MDR* genes in drug-resistant murine and human cell lines are often manifested as the DM configuration, whereas in Chinese hamster cells, they appear as ABR (138).

In early observations, ABR-containing amplified DNA in hamster drug-resistant variants were often localized distal to the single-copy locus on the same chromosome (138) (Fig. 12B). The underlying mechanism of this cytogenetic manifestation of DNA amplification is consistent with the break-fusion-bridge (B-F-B) mechanism. According to this model (Fig. 12A), an initial isochromatid break distal to the target gene of a specific cytotoxic agent produces uncapped chromosomes. After isochromatid fusion and replication, the resulting dicentric chromosome moves toward two opposite poles during the telophase of the cell cycle. An additional

FIG. 12. Effects of ROS on amplification of the *mdr1* gene. (A) Schematic diagram showing the break-fusion-bridge (B-F-B) mechanism of amplification of the *mdr1* gene in MDR CHO cells. The effects of ROS on factors that regulate chromosomal breakage and isochromatid fusion are indicated. (B) A photograph of fluorescence *in situ* hybridization showing the locations of single-copy *mdr1* (arrowheads) and amplified *mdr1* (arrows) on the Chinese hamster chromosomes. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article at www.liebert-online.com/ars).

break between the centromere and the target gene of the dicentric chromosome occurs. The resultant chromosome contains a duplicated chromosomal segment with inverted polarities that are bordered by the target (single-copy) gene and the distally located amplified gene (Fig. 12A). This rather consistent chromosomal abnormality is found in many Chinese hamster drug-resistant cell lines (138). Chinese hamster *mdr1a* is located at 1q26 and the amplified *mdr1a* clustered at 1q32, distal to the single copy locus. Similar results also were observed in MDR cell lines. *BCRP* is located at chromosome 4q21-4q22, and amplified *ABCG2* sequence peaks at 4q21-4q22 in multidrug-resistant variants with acquired resistance to *ABCG2* drug substrates (65).

This B-F-B model of DNA amplification underscores the importance of the initial chromosomal break that triggers the B-F-B cycle. Kuo *et al.* (139) observed that in three independently established MDR-CHO cell lines selected with vincristine, vinblastine, and Adriamycin, the break sites are all located on chromosomal 1q31. Because the cytotoxic agents used in the selection of MDR cells exhibit different modes of cytotoxic mechanism yet gave rise to the same location of chromosomal breakage, it was hypothesized that the breakage site is likely to be a chromosomal fragile site, and the initial event that triggers the B-F-B cycle is a stress-induced breakage at the fragile sites. This hypothesis was indeed demonstrated; CHO 1q31 is a major fragile site and is sensi-

tive to common fragile-site inducers, methotrexate and aphidicolin. The role of major chromosomal fragile sites in initiating DNA amplification was confirmed in many other drug-resistant variants, as well as in human tumor cell lines harboring amplified oncogenes with growth advantages (92, 160, 194, 238, 243). DNA amplification mediated by the B-F-B mechanism underscores two rate-limiting steps: the initial chromosomal breakage at the fragile site and the sister chromatid fusion. Both steps are modulated by redox signaling.

A. Role of redox signaling in chromosomal breakage at fragile sites

Chromosomal fragile sites have been traditionally considered loci that are intrinsically sensitive to cytotoxic assaults (135). Many cytotoxic agents used in MDR1 DNA-amplification studies such as vincristine, vinblastine, puromycin, and actinomycin D, have no known mechanism of action directly on chromosomal DNA. Therefore, the breakage associated with the DNA amplification initiated at the fragile site must be considered as secondary to the primary targets of these agents, consistent with the hypothesis of stress-induced cellular response (135).

Isochromatid breaks at chromosomal fragile sites produce one broken chromosome without a telomere and one acentric chromosome fragment. The latter will eventually disap-

pear after multiple runs of cell division. Chromosomes without telomeres, if uncapped, are unstable and prone to chromosomal abnormalities, including deletion, rearrangement, translocation, and fusion. Chromosomes that have lost a telomere may eventually be stabilized by *de novo* addition of a new telomere (11). The B-F-B cycle is observed only in cells defective in cell-cycle checkpoints, such as those with a p53-deficient background. This may explain why DNA amplification in drug-resistant tumor cells occurs at a frequency of $\sim 10^{-3}$ – 10^{-4} , whereas the frequency is much lower (10^{-8} – 10^{-9}) in wild-type p53-containing cells (159).

Numerous studies have suggested that oxidative stress that generates free radicals can induce DNA damage and genomic instability. Early studies from Schimke's group demonstrated that frequency of DNA amplification was increased in cells under stress conditions, such as pretreatments with UV (257), hydroxyurea (35), or hypoxia (211). Antioxidants NAC and GSH have been shown to suppress oxidative stress-induced DNA damage (207). Moreover, overexpression of *C-myc* has been tightly associated with the production of ROS, promotion of genomic instability, and tumorigenesis (263). Likewise, overexpressing antioxidant superoxide dismutase (SOD1) in transgenic mice increases chromosome breakage (118). These results provide evidence supporting the role of ROS in chromosomal breakage.

B. Role of redox signal in sister chromatid fusion

Isochromatid fusion is one of many repair mechanisms for DNA double-strand break (DSB). Sister chromatid fusion involved in the B-F-B model predicts the generation of an inverted repeat DNA sequence flanking the initial breakpoint. This is indeed the case found in drug-resistant cell lines containing amplified DNA (104, 259). In other studies using MDR cell lines containing highly amplified genes, no regions of extensive homology or inverted repeat sequences were identified at the amplicon junctions (146, 191). The formation of these junctions may be initiated by nonhomologous DNA end-joining (NHEJ) mechanism, or using the microhomology of DNA sequence at the junction (191).

NHEJ is the primary repair mechanism for DSB, which is error prone. In an artificial system where DSBs were generated by site-specific restriction enzyme cleavage (SceI), it was found that the frequency of NHEJ was $\sim 1,000$ times higher than that of homologous recombination, which uses a homologous DNA template for accurate repair. NHEJ pathway requires several factors, including a Ku70-86 complex for initial recognition of the DNA break, DNA protein kinase (DNA-PK) for activating repair protein at the breakage site, Artemis for potentiating DNA end-processing enzymes, and XRCC4-Ligase IV complex for religation of the broken DNA ends (40). At least some of the components in the NHEJ pathway are redox sensitive. For example, the function of the Ku complex is functionally regulated by redox mechanisms. Ku86(–/–) animals died during the postnatal weeks, but treating these Ku86(–/–) mice with antioxidant NAC prolonged the survival (208). Likewise, treatment with the antioxidant tempol increases survival of Ku70(–/–) cells in cultures (185). These results demonstrated that a defective Ku70-86 complex enhanced oxidative stress. The activities of the DNA-PK catalytic subunit are also regulated by redox conditions. Oxidative stress induced by the antitumor agent

chlorambucil in cultured ovarian cancer cells decreased DNA-PK catalytic subunit activity, whereas pretreating cells with antioxidant NAC increased DNA-PK activity by phosphorylating the threonine 2609 residue (10), demonstrating the reversibility of redox effects on DNA-PK activities. However, the roles of Ku70-86 and DNA-PKsc on sister chromatid fusion require further investigation.

VII. Redox Signaling in the Evolution of Intrinsic Multidrug Resistance in Cancer

A. Evolution of intrinsic multidrug resistance (upfront resistance)

As alluded to earlier, the expression of many multidrug transporters is inducible by oxidative stress. Moreover, many studies have shown the potential relation between the risk of carcinogenesis and ROS (256). A recent study demonstrated that elevated ROS production due to a genetic defect in mitochondrial respiratory complex 1 enhances tumor progress in an animal model (107). Thus, it is not surprising that elevated expression of these drug-resistance genes is found in tumors before chemotherapy. This intrinsic drug resistance has been found in various solid tumors, particularly in liver cancers, where *MDR1* gene upregulation is frequently observed (Fig. 13).

Here, I use *mdr1* gene expression in hepatocarcinogenesis as an example (Fig. 14). The liver is the body's major detoxification reservoir. It has a dual blood-supply (the hepatic artery and portal vein) system, enabling it to receive nutrients and toxic substances from virtually the entire body. The surface of hepatocytes contains abundant receptors, transporters, and carrier proteins that import a wide variety of xenobiotics, including plant alkaloids, antibiotics, and phytochemicals, and industrial toxic byproducts into the hepatocytes intracellularly. It is well known that liver cancer in animals can be induced by a wide variety of signals elicited by carcinogens, alcohol consumption, toxins, metals, and viral infections. Although these various agents have different cellular targets and different modes of cytotoxic effects, their common denominator is the formation of ROS, suggesting that oxidative stress plays an important role in hepatocarcinogenesis. Oxidative stress exerted by cytotoxic agents can also induce antioxidative defense mechanisms, including upregulation of antioxidant enzymes (SOD1, γ -GCSH, GPx, TrxR, catalase, etc.) and phase I [cytochrome P450, NAD(P)H quinone oxidoreductase] and phase II (GST, UDP glycosyltransferase) drug-metabolizing enzymes. These antioxidative defense mechanisms feed back to suppress the induced oxidative stress. Prolonged exposure to these cytotoxic agents produces persistent oxidative stress beyond the antioxidative stress that would lead to the development of liver cancers. Concomitantly, elevated expression of the *mdr1* gene is commonly observed in the hepatocellular carcinomas developed in these animals (256) (Fig. 14).

The implication that intrinsic drug resistance is present in human tumors can be found in the recent publication by Bracht *et al.* (33). These investigators showed that in two panels of human tumor cell lines, a 14-cell panel from this group and a 30-cell panel from the NCI, no correlations between the expression of *MRP1* and expression/activity of various antioxidative enzymes such as GPx, TrxR, GR, and GST, as

FIG. 13. Hypothetical model depicting the evolution of drug-resistant variants in cancer cells. Drug-resistant populations can be evolved from (a) cancer stem cells, which are intrinsically resistant to chemotherapy (open circle), (b) acquired drug-resistant cells (^) after eradicating the drug-sensitive cells (+) by chemotherapy, and (c) from intrinsic drug-resistant cells (*) that involve intrinsic upregulation of drug-resistance genes along with tumor development.

well as GSH levels, was found. Although expression of *Pgp1* and *MRP2* were not detectable, expression of *MRP1* were detectable in 10 of the 14 cell lines. Expression of *MRP1* in these cell lines correlates positively with resistance to vinblastine and etoposide, the substrates of the *MRP1* efflux pump. Many of these *MRP1*-expressing cell lines were from patients who had not been treated with chemotherapy, suggesting a role of *MRP1* in the intrinsic drug resistance.

B. Signal-transduction pathways in the intrinsic multidrug resistance

The signal-transduction pathways that regulate multidrug-resistance gene expression were discussed earlier. What follows is how these pathways interface between multidrug-resistance gene expression and carcinogenesis. Examples of these pathways are discussed.

1. The NF- κ B pathway. An important transcriptional activation pathway involved in the upregulation of multidrug resistance is the NF- κ B pathway. Activation of NF- κ B blocks programmed cell death induced by numerous cytotoxic agents, including chemotherapeutic agents, ionizing radiation, and cytokines. These cytotoxic agents induce ROS. Several studies indicate that NF- κ B induces a spectrum of gene expression to counter the accumulation of ROS (195). The cytoprotective measure of NF- κ B induced by cytotoxic agents such as doxorubicin is mediated by its downstream transcription mediator, Twist (196).

Activation of NF- κ B, as measured by the DNA-binding activity of transcription has been seen in many types of cancers. Several hundred NF- κ B target genes are present in the human genome, and many of them are involved in the immune responses, inflammation, apoptosis, cell proliferation, and angiogenesis. Persistent activation of NF- κ B has been

FIG. 14. Schematic diagram showing redox-regulated signal-transduction pathways that are important for tumorigenesis and for the evolution of multidrug resistance in tumors. Cytotoxic insults by various agents produce ROS, which are important regulators for various signal-transduction pathways that are implicated in tumorigenesis. ROS also are important in the regulation of multidrug-resistance gene expression, contributing to the evolution of intrinsic drug resistance in the tumors. ROS also are inducers for the expression of various antioxidant enzymes that feed back to suppress ROS levels.

suggested to induce cancer (119). Recent studies linked the roles of inflammation and cancer. In mouse models, suppression of NF- κ B signals by induction of I κ B superrepressor expression reduced liver cancer progression and prevented the development of HCC in an established HCC model (the *mdr2*-knockout mouse). Reactivation of NF- κ B leads to rapid tumor development (197). Moreover, deleting IKK β in the intestinal epithelial cells reduced colitis-associated tumor incidence resulting from increased epithelial apoptosis during tumor development (82). However, animals with targeted deletion of IKK β in myeloid cells are more susceptible to endotoxin because of elevated expression of pro-IL-1 β . Similar results also were observed by using IKK β inhibitor ML120B by oral administration. Likewise, Luedde *et al.* (164) observed that ablation of IKK γ in liver parenchymal cells increased the expression of proinflammatory cytokines and chemokines, resulting in the induction of steatohepatitis and spontaneous HCC. These animals showed a striking improvement with a diet supplemented with the antioxidant butylated hydroxyanisole. These results strongly suggest that increased oxidative stress elicited by the ablation of NF- κ B signaling is responsible for the proinflammatory response. Collectively, these results further suggest that NF- κ B can function as either a cancer-promoting transcription factor or a cancer suppressor, depending on the cancer model.

2. The PI3 kinase pathway. The PI3K pathway is frequently activated by genomic mutations in many types of human cancers (37). Its effects include elevated expression of its subunit (p110), enhanced activities of its downstream effector (Akt), mutations of its suppressor protein phosphatase and tensin homolog deleted on chromosome 10 (PTEN), or a combination of these. The PI3K pathway can be activated by a wide variety of extracellular influences such as growth factors, carcinogens, and hepatitis viral infection (256), and many of these agents are inducers of multidrug transporter gene expression. In prostate cancer cells, it was found that PTEN-negative cells exhibited elevated resistance to doxorubicin and paclitaxel. Inhibition of PI3K with LY29402 potentiates the sensitivity to these antitumor agents (144). It has also been demonstrated that treatment of multidrug-resistant colon cancer cells with the PI3K-inhibitor LY294002 sensitized cells to doxorubicin treatment (144).

It has been demonstrated that PI3K/Akt signaling regulates *c-Myc* promoter activity, mRNA stability, and protein stability through its downstream genes, *GSK3 β* and *β -catenin* (132). Furthermore, Akt phosphorylates and sequesters transcription factors FOXO3a, Mad-1, and Miz-1, which inhibit transactivations of *c-Myc* target genes (293). These observations suggest that this signaling pathway can regulate *c-Myc* positively and negatively. PI3K/Akt signaling also regulates the expression of HIF-1 α (102). Both *c-Myc* and HIF-1 α are regulators of oncogenesis as well as the expression of multiple multidrug-resistance efflux pumps, as described earlier.

3. The p53 pathway. The p53 pathway is one of the major tumor-suppressive mechanisms in mammals. Aberrations in p53 signaling, due to either mutations of p53 or dysfunction of its interacting proteins (MDM-2, MDM-X, P14/P19 ARF), have been found in ~50% of human malignancies (154).

The p53 pathway can be activated by a wide variety of external and internal signals, including DNA damage by UV or γ -irradiation, hypoxia, therapeutics, nutritional deprivation, heat shock, oncogenic activation, *etc.* Many of these assaults generate ROS, important regulators of the p53 pathway that controls the expression of hundreds of targeting genes (154, 217). At least two redox-active proteins, redox factor-1 and thioredoxin reductase, have been suggested to regulate the basal level activity of p53. The former functions as a positive regulator by stabilizing (and therefore enhancing) DNA-binding activity of p53 (72), whereas the latter functions as a negative regulator (89, 205, 230). The stability and activity of p53 are markedly enhanced by post-translational modifications such as phosphorylation by the ataxia-telangiectasia mutated (ATM) protein, methylation by methylase, and acetylation by acetyltransferase [for review, see ref. (156)]. Moreover, p53 is subjected to ubiquitination by ubiquitin ligase conferred by MDM-2 protein, which leads to degradation, with a half-life of 6–10 min. By itself, p53 is redox active because it contains several Cys residues at the DNA-binding domains. These Cys residues are important for DNA binding and S-glutathionylation by GSH reduces the DNA-binding activity (267).

The role of p53 in drug resistance has been explored in *in vitro* cell-culture studies and *in vivo* systems. Because the p53 signaling pathway can be activated by the therapeutics, one would anticipate that p53 may play a role in drug resistance. Early *in vitro* study demonstrated that wild-type p53 suppressed the expression of human *MDR1* and *MRP1* (229). However, the effects of p53 expression on cancer chemotherapy are complex (72, 272). Clinical investigations showed a correlation between p53 mutations and resistance to cancer chemotherapy in some cancer types, whereas in other tumor types, p53 mutations were correlated with drug sensitivity (72, 272). Given the complexity of the p53 pathophysiologic network in apoptosis, senescence, growth arrest, and DNA damage response, *etc.*, it is not surprising that the role of p53 in cancer chemotherapy is very complex.

VIII. Clinical Significance of Redox Signaling in Multidrug Resistance and Therapeutic Opportunities

Since the identification of Pgp as the determinant for the multidrug resistance was established in cultured cells, the importance of its roles in clinical drug resistance has become apparent. Accurate assessment of the role of multidrug transporters in clinical settings requires reliable methods of quantification of the expression levels of these transporters. The expression levels of *MDR1/Pgp1* in clinical specimens have mostly been documented by assaying mRNA levels with real-time polymerase chain reaction (RT-PCR) or by immunohistochemistry for protein levels or both. Both assay systems have inherent weaknesses, including contamination of normal tissues in the tumor specimens (in RNA measurement), and poor sensitivity and specificity (cross-reactivity) and quantifiability (in immunohistochemistry). Moreover, a caveat indicates that levels of expression may not faithfully reflect the functionality of the transporters. For a functional ABC transporter in a clinical setting, at least two criteria should be met: (a) its expression levels should be inversely correlated with the chemosensitivity of antitumor

agents that are known to be substrates of the transporter; and (b) an enhanced response to chemotherapy should be observed when inhibitors or reversal agents are used. The availability of tumor specimens often compromises the ability to perform a thorough study. Given these difficulties, it is not surprising that in-depth studies of the role of the *MDR* transporter in clinical drug resistance is needed, particularly in the areas of solid tumors (149).

Despite this, the expression of *MDR1/Pgp1* has been studied in a wide variety of cancers, including leukemia, myeloma, breast cancer, lung cancer, ovarian cancer, sarcoma, bladder cancer, and cervical cancer (149). We can still correlate cancers that are intrinsically resistant to chemotherapy, such as HCC, renal cell carcinomas, and colorectal cancers with elevated levels of *MDR1* expression (71), although it should be noted that high levels of *MDR1* expression are present in the original neoplastic tissues. Many studies have tried to determine the correlation between expression levels of *MDR1/Pgp1* in these tumors and responses to chemotherapy with antitumor agents that are substrates of *MDR1/Pgp1*. Some studies showed positive correlations between reduced *MDR1/Pgp1* expression levels and improved response rates in some tumor types, whereas other tumor types failed to find such a correlation (134, 149). Expression of the *MRP* family and *ABCG2* in leukemia and in a wide spectrum of solid tumors has been reported [see review in ref. (214)], and similarly observations have been recorded. Among these various tumor types, leukemias have been extensively studied and yielded conflicting results (265). Elevated expression of *MDR1/Pgp1* in adult AML has been shown to correlate with reduced response rates (30, 198, 276, 295). However, in a phase III randomized study of AML patients with inclusion of the *MDR1* inhibitor, valspodar (PSC833), in the mitoxantrone, etoposide, and cytarabine treatment protocol did not improve complete response and overall survival (81). The impacts of *MDR1/Pgp1* (36), the *MRP* family (200, 244), and *BCCRP* (214) in the treatment outcomes of these diseases remain to be conclusively established.

Several approaches have been undertaken to combat multidrug resistance. Conventional approaches include the redesigning of antitumor drugs in such a way that the new agents can escape being eliminated by multidrug transporters. Natural antitumor agents with multiple rings and hydrophobic properties generally are good substrates for these transporters. Therefore, drug design by decreasing the hydrophobicity of the original compound that may reduce the affinity of new agents with Pgp has been rationalized (34). However, this approach so far has proven difficult. Unlike the conventional substrate-enzyme interactions, effecting a small change in a drug structure is likely difficult to produce a substantial reduction in its affinity for the transporter. This is because the drug-binding sites in these multidrug transporters are large and flexible (95). Moreover, merely reducing lipophilicity in drug design may not be sufficient for a successful solution when the complex mechanism of *Pgp1*-mediated drug transport as a whole is considered. It is most important that the parameters that affect the kinetics of drug influx and efflux across the cell membrane ultimately contribute to the intracellular drug accumulation. For example, anthracycline analogues have been designed to circumvent *Pgp1*, thereby enhancing therapy ef-

ficacy for treating *MDR* cells. Four anthracycline derivatives, doxorubicin, daunorubicin, 8-(*S*)-fluoroidarubicin, and idarubicin are extruded by Pgp at comparable rates, perhaps because of the presence of an amino sugar group in these four drugs. However, these four drugs have considerable variations in the kinetics of uptake of the drugs, as reflected in differences in cell killing (167).

Early studies in cultured cells showed that the transporter activity of *Pgp1* could be inhibited by verapamil and cyclosporin *A* stimulated considerable interest in clinical trials (189). However, these first-generation *Pgp1* reversal agents had only limited success because of toxicity due to pharmacokinetic interactions between the chemotherapeutic agents and the reversal agents. Subsequent clinical trials using the second and third generations of Pgp inhibitors, including tariquidar (XR9576) (164), valspodar (PSC833) (19), zosuquidar (LY335979) (143), ONT-093 (OC-144-093) (49), and elacridar (GF120918) (199), have not generated promising results and require further evaluations. These approaches generally have multiple difficulties, including achieving sufficiently high doses of nontoxic *MDR*-reversal agents in the clinical setting, the inability to predict that suppression of Pgp activity occurs at such high levels, and the mechanistic importance of Pgp expression in the tumors, as discussed earlier.

Is redox signaling a viable target for overcoming drug resistance in cancer chemotherapy? Recent studies have demonstrated that natural products with antioxidant capacities, such as tea polyphenol and epigallocatechin gallate, exhibited reversal effects of multidrug resistance in KB-A-1 cells by 5.2- and 2.5-fold, respectively, but not in drug-sensitive parental cells (172). Treatment of drug-resistant cells with these agents also reduced intracellular ROS levels. These observations suggest that inhibition of *MDR* in KB-A-1 cells may be attributed in part to the suppression of ROS. Another antioxidant, curcumin, which is a polyphenol, has been shown to be an inhibitor of *MDR1*, *MRP1*, and *BCRP*. Nontoxic concentration of curcumin sensitized the *BCRP*-expressing cells to mitoxantrone, topotecan, SN-38, and doxorubicin. Curcumin apparently is not a substrate of these ABC transporters, but its inhibition may be through stimulating *BCRP*-mediated ATP hydrolysis. Photoaffinity-labeling experiments showed that curcumin also inhibits substrate binding to the *BCRP* transporter (46). Likewise, natural diterpenes, triterpenes, and carotenoids isolated from vegetables and medicinal plants have been shown to enhance substrate accumulation in *MDR* cells (180). Although the clinical benefits of these antioxidants remain to be demonstrated, they may offer a broad spectrum of modulators in anti-*MDR* chemotherapy.

Several redox-relevant transduction pathways have been shown to regulate multidrug-resistance transporter gene expression. Therefore, modulation of these specific pathways may be of value for controlling drug sensitivity. Several NF- κ B inhibitors have been developed (266). The proteasome inhibitor, bortezomib (velcade, PS-341), has been approved for the treatment of AML, multiple myeloma, and other solid tumors by virtue of its ability to target aberrantly activated NF- κ B in these tumors. However, bortezomib is a substrate of Pgp that may diminish its effectiveness in the combination therapy for cancer overexpressing Pgp (176, 218). The PI3K/AKT pathway is implicated in the pathogenesis of

many cancers and is involved in the redox regulation of the multidrug resistance gene. Many inhibitors for this pathway have been under clinical trials, and others are under development (37). LY294002, a specific inhibitor of PI3K/AKT kinase, was found to sensitize vincristine-resistant leukemia cells (18).

HIF-1 has been implicated in human cancer development by activating a whole host of genes that are involved in angiogenesis, oncogenic transformation, glucose metabolism, invasion stem cell physiology, and upregulation of the ABC drug transporter (Fig. 6) (234, 235). Overexpression of HIF-1 α , perhaps due to intratumoral hypoxia, has been frequently observed in patients of several tumor types [for review, see ref.(202)]. This makes HIF-1 α an attractive target of cancer therapy (202). Many antitumor agents have been shown to modulate the activities of HIF-1 α by various mechanisms, including decreased HIF-1 protein expression levels, decreased interacting with its DNA binding, and therefore its transactivation of gene expression (233). It is of interest to note that inhibitors to HIF-1 α suppressing redox signaling have been in clinical trials for antitumor efficacy (273).

Because of the complexity underlying the mechanisms of carcinogenesis and the emergence of drug resistance in the course of cancer chemotherapy, combination therapy using multiple agents simultaneously targeting multiple pathways has proven to be more effective than that with single agents. Many hundreds of genes are regulated by each of these individual pathways, but only a subset of genes is relevant to cancer progression and drug resistance. Moreover, the contributions of these signal-transduction pathways may vary among different types of cancer. Thus, identifying an effective treatment protocol will be a long process, despite the vast amounts of information that have been generated from preclinical investigations.

IX. Redox Signaling in Multidrug-Resistant Cancer Stem Cells

The concept of cancer-initiating cells was originally developed from the work in human AML. Lapidot *et al.* (142) identified a rare population of CD34⁺CD38⁻ cells from patients with AML, which, when infused into severe combined immune-deficient mice, resulted in leukemic blast generation, whereas similar infusions with more committed CD34⁺CD38⁺ lineage cells or CD34⁻ cells failed to produce leukemia. CD34⁺CD38⁻ cells maintain the differentiating and proliferative capacity with potential self-renewal properties in nonobese diabetic mice with severe combined immunodeficiency disease (29). Hematopoietic stem cells (HSCs) remain the best-characterized system.

A. Multidrug-resistant hemopoietic stem cells

Evidence indicating that ABC transporters play a critical role in protecting hematopoietic stem cells was originally described by Chaudhary and Ronninson (45). These investigators showed that populations of bone marrow cells exhibiting reduced retention of fluorescent rhodomin (Rho 123) and elevated expression of *MDR1* are associated with hematopoietic progenitor (CD34⁺) cells. This population of cells, commonly referred to as side population (SP), can be isolated by fluorescence-activated cell sorting (FACS) by the virtue of their enhanced ability to efflux fluorescent dyes

such as Rho123 and Hoechst 33342 (78). ABCG2 was subsequently identified and characterized as a novel stem cell marker (292). Interestingly, ABCG2-derived SP cells were also found within embryonic stem (ES) cells, as well as many solid tissues. By using knockout strategies, it was demonstrated that no significant hematologic defects were associated with *mdr1a*(-/-)*mdr1b*(-/-) compound mice (225), and a normal population of SP cells was observed in the bone marrow, suggesting that other ABC transporters may play a compensatory role in the stem cell population (39, 292). However, ABCG2(-/-) animals showed a reduced SP population and were significantly more sensitive to mitoxantrone in drug-treated transplanted mice (291), demonstrating that ABCG2 constitutes the major SP cells and is associated with drug resistance. It should be noted that, strictly speaking, the SP isolated by FACS may not be necessarily enriched in ABC transporters, because reduced fluorescence intensity is not always correlated with elevated expression levels of efflux pumps. Many factors can affect the fluorescence intensity, including reduced rates of dye uptake, reduced stability of the fluorochromes, enhanced quenching of fluorescence due to intracellular sequestration of the fluorochromes and their interactions with cellular constituents and organelles, etc.

HSCs reside in bone marrow where oxygen supplies are low and are sensitive to oxidative stress. Loss of the mitochondrial antioxidative stress enzyme SOD2 in HSCs enhanced protein oxidative damage and resulted in erythroid hypoplasia (74). Interestingly, maintenance of the self-renewal capacity of HSCs requires a functional ataxia-telangiectasia mutated (*ATM*) gene. *Atm*(-/-) mice showed drastically reduced HSC numbers that are associated with elevated ROS production. These phenotypes are reversed by using the membrane-permeable antioxidant, NAC (110). Further study revealed that ROS-induced defects in HSC maintenance were due to p38 MAPK phosphorylation (111). These results demonstrated that ROS play an important role in the regulation of HSC homeostasis.

Elevated expression of BCRP is present in SP cells derived from a wide range of tissues, including muscle, heart, lung, intestine, and cornea. Perturbation of *BCRP* expression affects the SP cell phenotype. Downregulation of ABCG2 by siRNA depletes retinal SP cells and promotes their differentiation (24). These results correlate the expression of *BCRP* expression with the maintenance of SP cells.

B. Multidrug-resistant cancer stem cells of solid tumors

Cumulative evidence has demonstrated that SP cells are present in a wide variety of solid tumors, as well as their derived cell lines (58, 97), including lung cancer cell lines and human lung cancer samples (97), hepatocellular carcinoma (50), breast cancer (6, 241) mesenchymal tumors [osteosarcomas, chondrosarcomas, leiomyosarcomas, cordomas (275)], gastrointestinal cancer cells (90), murine ovarian cancer (246), etc. In some studies, when ABCG2 expression levels were analyzed, SP cells displayed elevated expression of ABCG2 as well as other ATP-binding cassette transporters. The ABCG2 and ABCB1/*MDR1* genes are expressed in normal stem cells and in most tumor stem cells (125, 222, 292). ABCG2 levels were reduced when stem cells were induced to differentiate. Levels of ABCG2 decreased as MCF-7 SP cells

were treated with TGF- β which induces epithelial-mesenchymal transition (285).

Recent studies have identified an additional ABC transporter, ABCB5 (124, 223), as a marker for human melanoma stem cells. ABCB5 was originally characterized as a determinant of membrane potential that controls cell fusion in skin progenitor cells. ABCB5 functions as a Rho 123 efflux pump and a major efflux mediator of doxorubicin and contributes to chemoresistance to doxorubicin (73). ABCB5 marks CD133-expressing progenitor cells, a surface marker protein that is present in the stem cell population of many solid tumors, including glioma (17), colon cancer (190), and prostate cancer (54). ABCB5 appears to be important for the growth of melanoma in animal xenografts, because administration of monoclonal antibody directed at ABCB5 suppresses tumor growth (223), providing a potential strategy for targeting cancer stem cells by using the anti-ABC transporter approach. However, it remains to be investigated whether ABCB5 is the major efflux transporter that contributes to the inherent resistance of melanomas to many chemotherapeutic interventions.

C. Signaling pathways in cancer stem cells

In addition to the efflux multidrug transporters, several crucial signaling pathways have been elucidated for cancer stem cell biology, including Wnt/ β -catenin, Notch, sonic

hedgehog, Bmi-1, the Hox family, and PTEN (161). Here, only the pathways that are most relevant to multidrug resistance are discussed.

1. **The Wnt/ β -catenin signaling.** The Wnt signal-transduction pathway is a well-conserved signaling process through evolutionary processes. It plays an important role in regulating cellular proliferation, differentiation, motility, and survival/death (248). Wnt proteins are 39- to 46-kDa secretory glycoproteins that bind the cell-surface receptors, Frizzleds (Fig. 15B). The Wnt signal is frequently activated in various human cancers (175). Activation of Wnt signaling prevents cytoplasmic β -catenin from degradation, allowing it to translocate into the nucleus, where it binds and activates transcriptional repressor T-cell factors (TCFs), resulting in upregulation of the target genes, one of which is human MDR1. The promoter of *MDR1* contains a cluster of TCF/ β -catenin-responsive elements through which expression of *MDR1* by this transcriptional machinery is regulated (281). One of the intracellular repressors is adenomatous polyposis coli (APC). Deletions of *Apc* alleles result in the development of intestinal polyps. Interestingly, this group of investigators found that expression of murine *mdr1a/mdr1b* suppressed the development of colonic polyps in *APC*^{min/+} mice (280), suggesting that *mdr1a/mdr1b* may function as a tumor suppressor in this tumor model.

FIG. 15. The Notch, Wnt, and SHH signaling pathways. (A) Notch pathway: Ligands (Delta or Jagged) binding to the receptor trigger proteolytic cleavage by γ -secretase, resulting in release of intracellular domain of the receptor (NICD), which subsequently forms a complex with the transcription factor CSL and cofactor Mastermind-like (MAML) family to activate target gene expression. (B) Wnt pathway: In the absence of Wnt ligand, β -catenin is complexed with a group of proteins, including adenomatous polyposis coli (APC) and Axin, where it is phosphorylated by casein-kinase 1a (CK1a) and glycogen synthase kinase 3 β (GSK3 β). On activation by the binding of Wnt ligand to the Frizzled and lipoprotein-related protein (LRP) receptors, Frizzled then binds to disheveled (Dsh), resulting in LRP phosphorylation, and Axin is translocated to the cell membrane. β -Catenin is accumulated and translocated to the nucleus and interacts with the T-cell factor (TCF) transcription factor (adapted from ref. 7). (C) SHH pathway: the receptor of SHH is the tumor-suppressor gene product, PTCH, which represses the activation of smoothened (Smo). Binding of SHH releases this repressive effect on Smo by PTCH, activating glioblastoma transcription factor (Gli1, 2, or 3 family), which then activates the transcription of target genes.

The involvement of Wnt/ β -catenin signaling in redox regulation can be found from the following studies. β -Catenin is a cofactor that activates FoxO transcription factors, which are regulated by PI3K/Akt oxidative-stress signaling (69), the same stress signaling that regulates the expression of many MDR transporters. Moreover, members of FoxO have been shown to protect HSCs from oxidative stress. Conditional triple deletion of *FoxO1*, *FoxO3*, and *FoxO4* in the adult hematopoietic cells resulted in marked increase in ROS levels with defective myeloid-lineage expansion and long-term repopulating of HSCs. Treatment with the antioxidant NCS reversed the observed phenotype in HSCs (260), further supporting the role of ROS in the maintenance of the HSC population.

2. The Notch signaling. Notch was discovered as an oncogene in humans that gives rise to T-cell leukemia, bearing the t(7,9)(q34,q34) translocation (68). The Notch signaling pathway is well preserved from nematodes to humans. Four Notch receptors exist for four Notch ligands. On binding of Notch ligands (Delta or Jagged) to the receptors, proteolytic cleavages by γ -secretase liberates the Notch intracellular domain (NICD), which then translocates into the nucleus, and transactivates the target genes by complexing with the transcription factor CSL and cofactors of the Mastermind-like (MAML) (Fig. 15A). Recent studies demonstrated that the Notch signaling pathway plays important roles in modulating cell-fate decisions, differentiation, survival/apoptosis, and cell-cycle control. Importantly, Notch signaling has an important function in stem cell biology. Manipulating the expression of Notch ligand or its downstream target affects the self-renewal capacity of HSCs (27).

The Notch signaling is also redox regulated. Early study demonstrated that mutations in Notch were associated with mitochondrial dysfunction (57). More recent study demonstrated that disruption of Notch signaling by γ -secretase inhibitors resulted in the accumulation of ROS (25). Furthermore, constitutive activation of the Notch signal by overexpressing NICD results in the upregulation of ABCG2, whereas cells treated with Notch signal inhibitor reduced the ABCG2 population, suggesting that Notch signaling regulates ABCG2 and SP populations (24). It remains to be determined whether upregulation of ABCG2 by Notch signaling involves oxidative stress.

3. The sonic hedgehog signaling. The sonic hedgehog (SHH) signaling pathway performs various important functions, which include neural tube patterning, left-right symmetry, polarizing activity in the limb, and morphogenesis of various organs (8). It also plays an important role in the development of various cancers. The receptor for SHH is the product of the tumor-suppressor gene, patched transmembrane receptor (*PTCH*). In the absence of SHH ligands, *PTCH* activates smoothened (Smo) membrane protein. Activation of SHH signals elicited by SHH binding to *PTCH* relieves the repression of Smo, thereby activating glioblastoma transcription factors Gli1, Gli2, and Gli3, and turning on the expression of the targeting genes (Fig. 15C). Abnormalities in the SHH signaling pathway, including mutations of *PTCH2*, *Smo*, *Gli1*, and *Gli2*, contribute to the development of malignancies in humans (44).

A recent study demonstrated that inhibiting SHH signaling by cytopamine enhanced resistance to docetaxel, methotrexate, and etoposide by upregulation of the expression of Gli-1, resulting from activations of *MDR1* and *BCRP* expression. Downregulation of Gli expression by the siRNA approach reduced the expression levels of *MDR1* and *BCRP*. These results demonstrate that SHH signaling regulates the expression of these ABC transporters (239) and supports their dual roles in drug-resistance gene regulation and stem cell maintenance.

X. Therapeutic Opportunities for Cancer Stem Cells

Cancer stem cells share many properties with those found in leukemia-initiating cells. They are rare in numbers (10^{-3} – 10^{-5} % of all cancer cells) and normally reside in an environment where O_2 tension is low. They are generally replicatively quiescent. Some cancer stem cells overexpress multidrug transporters, but this is not the rule. They may be less sensitive to oxidative stress exerted by cytotoxic agents, but redox signals play an important role in the maintenance of their “stemness.” They exhibit highly proliferative activity in xenotransplantation in adaptive and innate immunity-deficient animals. In some cases, a few hundred cells can initiate tumors in these animals (212).

It is thought that traditional treatments such as chemotherapy and radiation therapy do not readily eradicate cancer stem cells because of their intrinsic properties and because of their microenvironmental niche (Fig. 13). This raises an important question of whether cancer stem cells represent a drug-resistant population that contributes to therapeutic failure in initial treatment. Supporting evidence has been suggested by a recent finding that in the $CD34^+CD38^-$ leukemic cells candidate HSC subpopulation, enrichment of *MDR1* and/or *BCRP* mRNA levels were found in eight of 10 AML patients that were nonresponsive to daunorubicin plus cytarabine treatment; whereas it was found in none of seven patients with complete remission. No such association was found in more-differentiated $CD34^+CD38^-$ (96). These results suggest that expression of *MDR1* and *BCRP* in leukemic stem cells plays a role in the chemotherapy response in AML patients. Another support to this hypothesis may be the finding that radiation therapy for glioma resulted in an enriched stem cell population that is resistant to subsequent ionizing radiation by activating a DNA-damaging response ATM signaling (17).

Because HSCs can be isolated and engrafted back into the host, a strategy was developed for ex vivo gene therapy by using retroviral *MDR1* vector-transduced HSCs to protect the bone marrow from toxicity after high-dose chemotherapy. Three clinical protocols (88, 94, 181) have been conducted involving HSCs collected from patients with breast cancers. In these protocols, a replication-incompetent retrovirus containing the *MDR1* gene in the presence of stem-cell factors was ex vivo transduction into the HSC population, followed by autologous bone marrow transplantation [for review, see ref. (60)]. The results are disappointing because of low ex vivo transduction efficiency in combination with low levels of *MDR1* expression. These studies have several caveats. Transduction of murine bone marrow cells with a functional *MDR1* retroviral vector resulted in an almost 2-log increases in SP cell numbers, whereas functionally inac-

tive MDR1 mutant cDNA was unable to amplify phenotypically defined SP cells and functionally defined repopulating cells. Another caveat is that forced expression of *MDR1* in murine bone marrow cells resulted in the development of an adverse myeloproliferative syndrome in transplanted mice, characterized by high peripheral white blood cell counts due to myeloid progenitor accumulation. It was also found that the role of MDR1 protein in transplanted bone marrow did not provide a benefit in the treatment of chronic myelocytic leukemia model (CML) with imatinib (296). Moreover, the amount of ABCG2 expression in the myeloid leukemia cells (AML) was very low to reach the levels that are comparable for drug-resistance levels *in vitro* (1). However, it is important to note that no detectable *ex vivo* expansion of the SP population was found when the *MDR1* transduction experiments were carried out in a nonhuman primate model, perhaps resulting from the differences in transduction efficiencies between the mouse and rhesus monkey (232). Future efforts should be focused on technical aspects by improving the transduction efficacy as well as levels of drug-resistance gene expression by using a strong promoter in the recombinant vectors. The potential adverse effects of overexpressed MDR product in the repopulated bone marrow also should be investigated.

Despite these disappointing results, HSCs may still have value for cell and gene therapy in the multidrug-resistance arena. It is conceivable that the maintenance of HSCs is a balance of self-renewal *versus* differentiation. Because of current knowledge of novel methods to expand stem cell self-renewal, one may generate a sufficient quantity of HSCs for transplantation into patients with marrow depletion due to chemotherapy (15, 29).

Several additional approaches can be considered for eradicating cancer stem cells. First, because many cancer stem cells overexpress *MDR1* and/or *BCRP*, the incorporation of inhibitors of ABC transporters into the chemotherapeutic regimens may be of value. For example, pheophorbide, a chlorophyll catabolite, is a highly specific inhibitor of ABCG2 (215). Second, because cancer stem cells maintain both self-renewal and differentiative ability, induction of differentiation into a committed cell lineage may abrogate their proliferative capacity. Many differentiation-inducing agents have been developed for the lineage studies of embryonic stem cells. Some of these inducers may be of value for this purpose (76). Third, many cancer stem cells exhibit elevated signaling-transduction pathways including Notch, Wnt, and SHH pathways. These signaling pathways are regulated by oxidative stress. Inhibitors for these pathways are being developed (215).

As many multidrug-resistance efflux pumps are membrane proteins, monoclonal antibodies tagged with antitumor agents against the extracellular domains of these membrane proteins may be of important value for the treatments of efflux pump-overproducing cancer stem cells. This approach may be particularly attractive, considering that cancer stem cells are rare inside the tumor mass so that high specificity of targeting is in demand. The successful use of a monoclonal antibody against ABCB5 in melanoma stem cells has at least proven the principle (223).

Because cancer stem cells share many common features with those found in normal stem cells, caution must be exercised to avoid harming the normal stem cells (such as those

in the bone marrow) during treatment. As better understanding of the role of cancer stem cells in the evolution of drug resistance is reached, one can expect that better treatment modalities targeting cancer stem cells also will be developed.

XI. Conclusions: Challenges and Perspectives

Almost three decades have passed since Pgp1 was first identified as a multidrug-resistance transporter. The field has generated enormous research enthusiasm in the hope that mechanistic insights can be translated into therapeutic benefit and that one of the most important problems in cancer chemotherapy—multidrug resistance—will be solved. It has been learned that multidrug resistance is much more complex than originally conceived. First, much redundancy exists in multidrug-resistance transporter genes in our genome. Each of these transporters not only displays overlapping substrate specificity but also is frequently co-expressed in many normal tissues and tumors. Second, the activities of these multidrug transporters can be upregulated by many extracellular influences. Some of the upregulation mechanisms are somewhat specific to particular drug transporters, but many are general and can affect many physiologic pathways. Third, compensatory mechanisms affect the expression of these transporters. We previously demonstrated that animals lacking *mdr1a* by knockout strategy upregulate *mdr1b* expression (16). Fourth, perhaps the most difficult task is delineating the unknown mechanisms associated with multidrug resistance evolved during the course of chemotherapy. Emergence of drug resistance is the result of a dynamic battle between cancer cells and chemotherapeutic agents. Drug-resistance mechanisms acquired during chemotherapy can be multifactorial, not only by the escape from the primary targets to which the chemotherapeutic agents act on, but also by the evolution of new mechanisms due to second hits. These new mechanisms can be due to genetic or epigenetic alternations, cancer cells and microenvironment interactions resulting in alterations of pharmacokinetic and pharmacodynamic properties of cancer drugs, and accessibility to the available drug delivery systems, *etc.* Although new antitumor agents will continue to be developed, it is anticipated that novel drug-resistance mechanisms will follow. Because of the versatility of redox signaling that could virtually reach almost every part of a cell and affect many signaling processes, it is anticipated that redox signaling will continue to play an important role in regulation of drug resistance with new therapeutics.

The challenges that face drug resistance in cancer chemotherapy are formidable and require that we translate the growing body of knowledge gained from drug-resistance research into effective therapeutic measures. Over a period of many years, evidence has accumulated suggesting that redox signaling is intimately associated with tumor progression. The enormous amount of information that has been generating from laboratory and preclinical investigations has revealed that redox signaling is a major stress-response process associated with the treatment of antitumor agents and is an important regulator of the expression and activity of many multidrug-resistance transporters.

The concept of drug-resistant stem cells in cancer chemotherapy has been around for many years. Recent studies

showing that elevated expression of multidrug-resistance efflux pumps (e.g., MDR/Pgp1, BCRP, and ABCB5) are associated with cancer stem cells demonstrate that drug-resistant stem cells and cancer stem cells share some common intrinsic properties, at least in some tumor types. These observations have brought together the two important fields of cancer research. Aside from the regulation of these ABC transporters, the important roles of redox signaling in controlling the “stemness” of these cancers are highlighted here.

Thus, strategies aimed at modulating cellular response with the use of redox modulators should be promising, because these strategies, in principle, provide a dual effect on cancer treatment: one is the cytostatic effect of tumor growth, and the other is the modulation of drug resistance in cancer chemotherapy. Nonetheless, one may have to bear in mind that whereas redox-targeting strategies may be promising, by themselves, may not be sufficiently effective to eradicate tumor cells, especially when the tumor burden is high. In this regard, integrating redox modulators into conventional chemotherapy, or other means of therapeutic interventions, may improve the overall treatment efficacy. All in all, the ultimate benefits of these strategies remain to be clinically documented.

Acknowledgments

The author's laboratory was supported in part by grants from National Cancer Institute (CA72404 and CA79085).

Abbreviations

2-AAF, 2-acetylaminofluorene; ABC, ATP-binding cassette; ABR, abnormal banding regions; Akt, protein kinase B; d-ALA, D-aminolevulinic acid; AML, acute myeloid leukemia; APAP, acetaminophen; APC, adenomatous polyposis coli; ARE, antioxidant response element; ASK1, apoptosis signal-regulating kinase 1; ATM, ataxia telangiectasia mutated gene; BCRP, breast cancer resistance protein; B-F-B, break-fusion-bridge; *BRCA1*, breast cancer 1; BSO, buthionine sulfoximine; CK1 α , casein-kinase 1 α ; CHO, Chinese hamster ovary; CK1, casein kinase 1; CML, chronic myelocytic leukemia; COX1, cyclooxygenase 1; COX2, cyclooxygenase 2; Cul3, Cullin 3; Cys, cysteine; CYP450, cytochrome P450; DM, double minute; DNMTs, DNA methyltransferases; NA-PK, DNA protein kinase; DNR, daunorubicin; DEN, diethylnitrosamine; DSB, double-strand break; Dsh, Dishevelled; EBV, Epstein-Barr virus; ER, endoplasmic reticulum; Ero1, ER oxidoreductin; ES, embryonic stem; FACS, fluorescence-activated cell sorter; FAD, flavin adenine dinucleotide; γ -GCSH, γ -glutamylcysteine synthetase heavy subunit; Gli, glioblastoma transcription factor; Glu, glutamine; Gly, glycine; GSH, reduced glutathione; GSSG, oxidized GSH; GST, glutathione S-transferase; HIF-1, hypoxia-inducible factor-1; HuR, a member of ELAV family AU-rich binding RNA-binding protein; GSK3 β , glycogen synthase kinase 3 β ; HADC, histone deacetylase; HBV, hepatitis virus B; HCC, hepatocellular carcinoma; HPETE, hydroperoxyicosatetraenoic acid; HSC, hematopoietic stem cell; I κ B, inhibitory protein kappa B; IKK, I κ B kinase; IL, interleukin; IRAK, interleukin-1 receptor-associated kinase; JNK, NH₂-terminal kinase; LAP, lipoprotein-related protein; LRP, lung resistance-related protein; LTC4, leukotriene C4; MAML, mastermind-like; MAPK-APK2, mitogen-activated protein

kinase-activated protein kinase 2; MeCp2, methyl-CpG-binding protein-2; MAPK, mitogen-activated protein kinase; MKK, MAP kinase kinase; MKKK, MAP kinase kinase kinase; MSD, membrane-spanning domain; MA, S-adenosylmethionine synthetase; MAT, methionine adenosyltransferase; MXR, mitoxantrone resistance protein; MDR, multidrug resistance; MRP, multidrug-resistance protein; NAC, N-acetylcysteine; NCID, Notch intracellular domain; NHEJ, nonhomologous DNA end-joining; NF- κ B, nuclear factor-kappa B; NIK, NF- κ B-inducing kinase; NQO, NAD(P)H quinone oxidoreductase; Nrf2, NF-E2-related factor; PDI, disulfide isomerase; Keap1, Kelch-like ECH-associated protein; PDK, phosphoinositide-dependent protein kinase; Pgp, P-glycoprotein; PHD, prolyl hydroxylase-domain protein; PI3K, phosphatidylinositol 3-kinase; PKC, protein kinase C; PP, peroxisome proliferator; PPAR γ , peroxisome proliferator-activated receptor γ ; PTCH, patched transmembrane receptor; PTEN, phosphatase and tensin homologue deleted on chromosome 10; redox, reduction-oxidative; Rho 123, rhodamine 123; ROS, reactive oxygen species; RILP76(RALBP-1), Ral-binding protein 1; SAH, S-adenosylhomocysteine; SAM, S-adenosylmethionine; SN-38, 7-ethyl-10-hydroxy-camptothecin; SHH, sonic hedgehog; Sin3, SWI-independent 3; Smo, smoothened; SOD1, superoxide dismutase 1; SP, side population; TCF, T-cell factor; TLR, Toll-like receptor; TMD, transmembrane domain; Trx, thioredoxin; VHL, von Hippel-Lindau.

References

- Abbott BL, Colapietro AM, Barnes Y, Marini F, Andreeff M, and Sorrentino BP. Low levels of ABCG2 expression in adult AML blast samples. *Blood* 100: 4594–4601, 2002.
- Abolhoda A, Wilson AE, Ross H, Danenberg PV, Burt M, and Scotto KW. Rapid activation of MDR1 gene expression in human metastatic sarcoma after in vivo exposure to doxorubicin. *Clin Cancer Res* 5: 3352–3356, 1999.
- Adachi T, Nakagawa H, Chung I, Hagiya Y, Hoshijima K, Noguchi N, Kuo MT, and Ishikawa T. Nrf2-dependent and -independent induction of ABC transporters ABCC1, ABCC2, and ABCG2 in HepG2 cells under oxidative stress. *J Exp Ther Oncol* 6: 335–348, 2007.
- Aleksunes LM, Slitt AL, Maher JM, Augustine LM, Goedken MJ, Chan JY, Cherrington NJ, Klaassen CD, and Manautou JE. Induction of Mrp3 and Mrp4 transporters during acetaminophen hepatotoxicity is dependent on Nrf2. *Toxicol Appl Pharmacol* 226: 7483, 2008.
- Allikmets R, Schriml LM, Hutchinson A, Romano-Spica V, and Dean M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. *Cancer Res* 58: 5337–5339, 1998.
- Alvi AJ, Clayton H, Joshi C, Enver T, Ashworth A, Vivanco MM, Dale TC, and Smalley MJ. Functional and molecular characterisation of mammary side population cells. *Breast Cancer Res* 5: R1–R8, 2003.
- Arbach H, Viglasky V, Lefeu F, Guinebreteiere JM, Ramirez V, Bride N, Boualaga N, Bauchet T, Peyrat JP, Mathieu MC, Mourah S, Podgorniak MP, Seignerin JM, Takada K, and Joab I. Epstein-Barr virus (EBV) genome and expression in breast cancer tissue: effect of EBV infection of breast cancer cells on resistance to paclitaxel (Taxol). *J Virol* 80: 845–853, 2006.
- Athar M, Tang X, Lee JL, Kopelovich L, and Kim AL. Hedgehog signaling in skin development and cancer. *Exp Dermatol* 15: 667–677, 2006.

9. Awasthi YC, Sharma R, Yadav S, Dwivedi S, Sharma A, and Awasthi S. The non-ABC drug transporter RLIP76 (RALBP-1) plays a major role in the mechanisms of drug resistance. *Curr Drug Metab* 8: 315–323, 2007.
10. Bacsi A, Kannan S, Lee MS, Hazra TK, and Boldogh I. Modulation of DNA-dependent protein kinase activity in chlorambucil-treated cells. *Free Radic Biol Med* 39: 1650–1659, 2005.
11. Bailey SM and Murnane JP. Telomeres, chromosome instability and cancer. *Nucleic Acids Res* 34: 2408–2417, 2006.
12. Baker EK and El-Osta A. MDR1, chemotherapy and chromatin remodeling. *Cancer Biol Ther* 3: 819–824, 2004.
13. Baker EK, Johnstone RW, Zalberg JR, and El Osta A. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs. *Oncogene* 24: 8061–8075, 2005.
14. Bakos E, Evers R, Szakacs G, Tusnady GE, Welker E, Szabo K, de HM van DL, Borst P, Varadi A, and Sarkadi B. Functional multidrug resistance protein (MRP1) lacking the N-terminal transmembrane domain. *J Biol Chem* 273: 32167–32175, 1998.
15. Bandler PE, Westlake CJ, Grant CE, Cole SP, and Deeley RG. Identification of regions required for apical membrane localization of human multidrug resistance protein (MRP2). *Mol Pharmacol* 74: 9–19, 2008.
16. Bao JJ, Lee BP, Stephens LC, Sahin AA, Van NT, Johnston DA, Ou CN, and Kuo MT. Elevated expression of hepatic proliferative markers during early hepatocarcinogenesis in hepatitis-B virus transgenic mice lacking mdr1a-encoded P-glycoprotein. *Mol Carcinog* 29: 103–111, 2000.
17. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, and Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. *Nature* 444: 756–760, 2006.
18. Barancik M, Bohacova V, Sedlak J, Sulova Z, and Breier A. LY294,002, a specific inhibitor of PI3K/Akt kinase pathway, antagonizes P-glycoprotein-mediated multidrug resistance. *Eur J Pharm Sci* 29: 426–434, 2006.
19. Bates SE, Bakke S, Kang M, Robey RW, Zhai S, Thambi P, Chen CC, Patil S, Smith T, Steinberg SM, Merino M, Goldspiel B, Meadows B, Stein WD, Choyke P, Balis F, Figg WD, and Fojo T. A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma. *Clin Cancer Res* 10: 4724–4733, 2004.
20. Bates SE, Robey R, Miyake K, Rao K, Ross DD, and Litman T. The role of half-transporters in multidrug resistance. *J Bioenerg Biomembr* 33: 503–511, 2001.
21. Belaiba RS, Bonello S, Zahringer C, Schmidt S, Hess J, Kietzmann T, and Grolach A. Hypoxia up-regulates hypoxia-inducible factor-1 α transcription by involving phosphatidylinositol 3-kinase and nuclear factor kappaB in pulmonary artery smooth muscle cells. *Mol Biol Cell* 18: 4691–4697, 2007.
22. Benassi B, Fanciulli M, Fiorentino F, Porrello A, Chiorino G, Loda M, Zupi G, and Biroccio A. c-Myc phosphorylation is required for cellular response to oxidative stress. *Mol Cell* 21: 509–519, 2006.
23. Benassi B, Zupi G, and Biroccio A. Gamma-glutamylcysteine synthetase mediates the c-Myc-dependent response to antineoplastic agents in melanoma cells. *Mol Pharmacol* 72: 1015–1023, 2007.
24. Bhattacharya S, Das A, Mallya K, and Ahmad I. Maintenance of retinal stem cells by ABCG2 is regulated by notch signaling. *J Cell Sci* 120: 2652–2662, 2007.
25. Bheeshmachar G, Purushotaman D, Sade H, Gunasekharan V, Rangarajan A, and Sarin A. Evidence for a role for notch signaling in the cytokine-dependent survival of activated T cells. *J Immunol* 177: 5041–5050, 2006.
26. Biedler JL, Chang TD, Scotto KW, Melera PW, and Spengler BA. Chromosomal organization of amplified genes in multidrug-resistant Chinese hamster cells. *Cancer Res* 48: 3179–3187, 1988.
27. Blank U, Karlsson G, and Karlsson S. Signaling pathways governing stem-cell fate. *Blood* 111: 492–503, 2008.
28. Bloom DA and Jaiswal AK. Phosphorylation of Nrf2 at Ser40 by protein kinase C in response to antioxidants leads to the release of Nrf2 from I κ Nrf2, but is not required for Nrf2 stabilization/accumulation in the nucleus and transcriptional activation of antioxidant response element-mediated NAD(P)H:quinone oxidoreductase-1 gene expression. *J Biol Chem* 278: 44675–44682, 2003.
29. Bonnet D and Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. *Nat Med* 3: 730–737, 1997.
30. Borg AG, Burgess R, Green LM, Scheper RJ, and Yin JA. Overexpression of lung-resistance protein and increased P-glycoprotein function in acute myeloid leukaemia cells predict a poor response to chemotherapy and reduced patient survival. *Br J Pharmacol* 103: 1083–1091, 1998.
31. Borst P and Elferink RO. Mammalian ABC transporters in health and disease. *Annu Rev Biol Chem* 71: 537–592, 2002.
32. Boscoboinik D, Debanne MT, Stafford AR, Jung CY, Gupta RS, and Epand RM. Dimerization of the P-glycoprotein in membranes. *Biochim Biophys Acta* 1027: 225–228, 1990.
33. Bracht K, Liebeke M, Ritter CA, Grunert R, and Bednarski PJ. Correlations between the activities of 19 standard anticancer agents, antioxidative enzyme activities and the expression of ATP-binding cassette transporters: comparison with the National Cancer Institute data. *Anticancer Drugs* 18: 389–404, 2007.
34. Brooks TA, O'Loughlin KL, Minderman H, Bundy BN, Ford LA, Vredenburg MR, Bernacki RJ, Priebe W, and Baer MR. The 4'-O-benzylated doxorubicin analog WP744 overcomes resistance mediated by P-glycoprotein, multidrug resistance protein and breast cancer resistance protein in cell lines and acute myeloid leukemia cells. *Invest New Drugs* 25: 115–122, 2007.
35. Brown PC, Tlsty TD, and Schimke RT. Enhancement of methotrexate resistance and dihydrofolate reductase gene amplification by treatment of mouse 3T6 cells with hydroxyurea. *Mol Cell Biol* 3: 1097–1107, 1983.
36. Broxterman HJ, Sonneveld P, van Putten WJ, Lankelma J, Eekman CA, Ossenkoppele GJ, Pinedo HM, Lowenberg B, and Schuurhuis GJ. P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy. *Leukemia* 14: 1018–1024, 2000.
37. Brugge J, Hung MC, and Mills GB. A new mutational AKTivation in the PI3K pathway. *Cancer Cell* 12: 104–107, 2007.
38. Brunelle JK, Bell EL, Quesada NM, Vercauteren K, Tiranti V, Zeviani M, Scarpulla RC, and Chandel NS. Oxygen sensing requires mitochondrial ROS but not oxidative phosphorylation. *Cell Metab* 1: 409–414, 2005.
39. Bunting KD. ABC transporters as phenotypic markers and functional regulators of stem cells. *Stem Cells* 20: 11–20, 2002.
40. Burma S, Chen BP, and Chen DJ. Role of non-homologous end joining (NHEJ) in maintaining genomic integrity. *DNA Repair (Amst)* 5: 1042–1048, 2006.
41. Cerutti PA. Prooxidant states and tumor promotion. *Science (New York)* 227: 375–381, 1985.

42. Chan K, Han XD, and Kan YW. An important function of Nrf2 in combating oxidative stress: detoxification of acetaminophen. *Proc Natl Acad Sci U S A* 98: 4611–4616, 2001.
43. Chandel NS and Budinger GR. The cellular basis for diverse responses to oxygen. *Free Radic Biol Med* 42: 165–174, 2007.
44. Chari NS and McDonnell TJ. The sonic hedgehog signaling network in development and neoplasia. *Adv Anat Pathol* 14: 344–352, 2007.
45. Chaudhary PM and Roninson IB. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. *Cell* 66: 85–94, 1991.
46. Chearwae W, Shukla S, Limtrakul P, and Ambudkar SV. Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin. *Mol Cancer Ther* 5: 1995–2006, 2006.
47. Chen Q, Yang Y, Li L, and Zhang JT. The amino terminus of the human multidrug resistance transporter ABCC1 has a U-shaped folding with a gating function. *J Biol Chem* 281: 31152–31163, 2006.
48. Chen Y, Yang Y, Miller ML, Shen D, Shertzer HG, Stringer KF, Wang B, Schneider SN, Nebert DW, and Dalton TP. Hepatocyte-specific Gclc deletion leads to rapid onset of steatosis with mitochondrial injury and liver failure. *Hepatology* 45: 1118–1128, 2007.
49. Chi KN, Chia SK, Dixon R, Newman MJ, Wachter VJ, Sikic B, and Gelmon KA. A phase I pharmacokinetic study of the P-glycoprotein inhibitor, ONT-093, in combination with paclitaxel in patients with advanced cancer. *Invest New Drugs* 23: 311–315, 2005.
50. Chiba T, Kita K, Zheng YW, Yokosuka O, Saisho H, Iwama A, Nakauchi H, and Taniguchi H. Side population purified from hepatocellular carcinoma cells harbors cancer stem cell-like properties. *Hepatology* 44: 240–251, 2006.
51. Cho SG, Lee YH, Park HS, Ryoo K, Kang KW, Park J, Eom SJ, Kim MJ, Chang TS, Choi SY, Shim J, Kim Y, Dong MS, Lee MJ, Kim SG, Ichijo H, and Choi EJ. Glutathione S-transferase mu modulates the stress-activated signals by suppressing apoptosis signal-regulating kinase 1. *J Biol Chem* 276: 12749–12755, 2001.
52. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM, and Deeley RG. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. *Science* (New York) 258: 1650–1654, 1992.
53. Cole SP and Deeley RG. Transport of glutathione and glutathione conjugates by MRP1. *Trends Pharmacol Sci* 27: 438–446, 2006.
54. Collins AT, Berry PA, Hyde C, Stower MJ, and Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. *Cancer Res* 65: 10946–10951, 2005.
55. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, and Colgan SP. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. *Cancer Res* 62: 3387–3394, 2002.
56. Copple IM, Goldring CE, Kitteringham NR, and Park BK. The Nrf2–Keap1 defence pathway: role in protection against drug-induced toxicity. *Toxicology* 246: 24–33, 2008.
57. de la Peña P, Bornstein B, del Hoyo P, Fernandez-Moreno MA, Martin MA, Campos Y, Gomez-Escalonilla C, Molina JA, Cabello A, Arenas J, and Garesse R. Mitochondrial dysfunction associated with a mutation in the Notch3 gene in a CADASIL family. *Neurology* 57: 1235–1238, 2001.
58. Dean M, Fojo T, and Bates S. Tumour stem cells and drug resistance. *Nat Rev Cancer* 5: 275–284, 2005.
59. Deeley RG and Cole SP. Substrate recognition and transport by multidrug resistance protein 1 (ABCC1). *FEBS Lett* 580: 1103–1111, 2006.
60. Deisseroth AB. Clinical trials involving multidrug resistance transcription units in retroviral vectors. *Clin Cancer Res* 5: 1607–1609, 1999.
61. Deng L, Lin-Lee YC, Claret FX, and Kuo MT. 2-Acetylaminofluorene up-regulates rat mdr1b expression through generating reactive oxygen species that activate NF-kappa B pathway. *J Biol Chem* 276: 413–420, 2001.
62. Dhakshinamoorthy S and Jaiswal AK. Functional characterization and role of INrf2 in antioxidant response element-mediated expression and antioxidant induction of NAD(P)H:quinone oxidoreductase gene. *Oncogene* 20: 3906–3917, 2001.
63. Dhillon AS, Hagan S, Rath O, and Kolch W. MAP kinase signalling pathways in cancer. *Oncogene* 26: 3279–3290, 2007.
64. Dolado I, Swat A, Ajenjo N, De Vita G, Cuadrado A, and Nebreda AR. p38alpha MAP kinase as a sensor of reactive oxygen species in tumorigenesis. *Cancer Cell* 11: 191–205, 2007.
65. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK, and Ross DD. A multidrug resistance transporter from human MCF-7 breast cancer cells. *Proc Natl Acad Sci U S A* 95: 15665–15670, 1998.
66. Ee PL, Kamalakaran S, Tonetti D, He X, Ross DD, and Beck WT. Identification of a novel estrogen response element in the breast cancer resistance protein (ABCG2) gene. *Cancer Res* 64: 1247–1251, 2004.
67. Ellgaard L and Ruddock LW. The human protein disulphide isomerase family: substrate interactions and functional properties. *EMBO Rep* 6: 28–32, 2005.
68. Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, Smith SD, and Sklar J. TAN-1, the human homolog of the *Drosophila* notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. *Cell* 66: 649–661, 1991.
69. Essers MA, de Vries-Smits LM, Barker N, Polderman PE, Burgering BM, and Korswagen HC. Functional interaction between beta-catenin and FOXO in oxidative stress signaling. *Science* (New York) 308: 1181–1184, 2005.
70. Finkel T. Oxygen radicals and signaling. *Curr Opin Cell Biol* 10: 248–253, 1998.
71. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, and Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. *Proc Natl Acad Sci U S A* 84: 265–269, 1987.
72. Fojo T. p53 as a therapeutic target: unresolved issues on the road to cancer therapy targeting mutant p53. *Drug Resist Update* 5: 209–216, 2002.
73. Frank NY, Margaryan A, Huang Y, Schatton T, Waaga-Gasser AM, Gasser M, Sayegh MH, Sadee W, and Frank MH. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. *Cancer Res* 65: 4320–4333, 2005.
74. Friedman JS, Rebel VI, Derby R, Bell K, Huang TT, Kuypers FA, Epstein CJ, and Burakoff SJ. Absence of mitochondrial superoxide dismutase results in a murine hemolytic anemia responsive to therapy with a catalytic antioxidant. *J Exp Med* 193: 925–934, 2001.
75. Ghosh S and Karin M. Missing pieces in the NF-kappaB puzzle. *Cell* 109(suppl): S81–S96, 2002.

76. Gil J, Stembalska A, Pesz KA, and Sasiadek MM. Cancer stem cells: the theory and perspectives in cancer therapy. *J Appl Genet* 49: 193–199, 2008.
77. Gomi A, Masuzawa T, Ishikawa T, and Kuo MT. Posttranscriptional regulation of MRP/GS-X pump and gamma-glutamylcysteine synthetase expression by 1-(4-amino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea and by cycloheximide in human glioma cells. *Biochem Biophys Res Commun* 239: 51–56, 1997.
78. Goodell MA, Brose K, Paradis G, Conner AS, and Mulligan RC. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. *J Exp Med* 183: 1797–1806, 1996.
79. Gort EH, Groot AJ, Derks van de Ven TL, van der Groep P, Verlaan I, van Laar T, van Diest PJ, van der Wall E, and Shvarts A. Hypoxia-inducible factor-1alpha expression requires PI 3-kinase activity and correlates with Akt1 phosphorylation in invasive breast carcinomas. *Oncogene* 25: 6123–6127, 2006.
80. Gotoh Y and Cooper JA. Reactive oxygen species- and dimerization-induced activation of apoptosis signal-regulating kinase 1 in tumor necrosis factor-alpha signal transduction. *J Biol Chem* 273: 17477–17482, 1998.
81. Greenberg PL, Lee SJ, Advani R, Tallman MS, Sikic BI, Letendre L, Dugan K, Lum B, Chin DL, Dewald G, Paietta E, Bennett JM, and Rowe JM. Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). *J Clin Oncol* 22: 1078–1086, 2004.
82. Greten FR, Eckmann L, Greten TF, Park JM, Li ZW, Egan LJ, Kagnoff MF, and Karin M. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. *Cell* 118: 285–296, 2004.
83. Gruber CW, Cemazar M, Heras B, Martin JL, and Craik DJ. Protein disulfide isomerase: the structure of oxidative folding. *Trends Biochem Sci* 31: 455–464, 2006.
84. Guo Y, Kotova E, Chen ZS, Lee K, Hopper-Borge E, Belinsky MG, and Kruh GD. MRP8, ATP-binding cassette C11 (ABCC11), is a cyclic nucleotide efflux pump and a resistance factor for fluoropyrimidines 2',3'-dideoxycytidine and 9'-(2'-phosphonylmethoxyethyl)adenine. *J Biol Chem* 278: 29509–29514, 2003.
85. Guzy RD, Mack MM, and Schumacker PT. Mitochondrial complex III is required for hypoxia-induced ROS production and gene transcription in yeast. *Antioxid Redox Signal* 9: 1317–1328, 2007.
86. Halim AB, LeGros L, Geller A, and Kotb M. Expression and functional interaction of the catalytic and regulatory subunits of human methionine adenosyltransferase in mammalian cells. *J Biol Chem* 274: 29720–29725, 1999.
87. Hamilton D, Wu JH, Aoui-Jamali M, and Batist G. A novel missense mutation in the gamma-glutamylcysteine synthetase catalytic subunit gene causes both decreased enzymatic activity and glutathione production. *Blood* 102: 725–730, 2003.
88. Hanania EG, Giles RE, Kavanagh J, Fu SQ, Ellerson D, Zu Z, Wang T, Su Y, Kudelka A, Rahman Z, Holmes F, Hortobagyi G, Claxton D, Bachier C, Thall P, Cheng S, Hester J, Ostrove JM, Bird RE, Chang A, Korbling M, Seong D, Cote R, Holzmayer T, Mechetner E, Heimfeld S, Berenson R, Burtness B, Edwards C, Best R, Andreoff M, Champlin R, and Deisseroth AB. Results of MDR-1 vector modification trial indicate that granulocyte/macrophage colony-forming unit cells do not contribute to posttransplant hematopoietic recovery following intensive systemic therapy. *Proc Natl Acad Sci U S A* 93: 15346–15351, 1996.
89. Hanson S, Kim E, and Deppert W. Redox factor 1 (Ref-1) enhances specific DNA binding of p53 by promoting p53 tetramerization. *Oncogene* 24: 1641–1647, 2005.
90. Haraguchi N, Inoue H, Tanaka F, Mimori K, Utsunomiya T, Sasaki A, and Mori M. Cancer stem cells in human gastrointestinal cancers. *Hum Cell* 19: 24–29, 2006.
91. Hayashi A, Suzuki H, Itoh K, Yamamoto M, and Sugiyama Y. Transcription factor Nrf2 is required for the constitutive and inducible expression of multidrug resistance-associated protein 1 in mouse embryo fibroblasts. *Biochem Biophys Res Commun* 310: 824–829, 2003.
92. Hellman A, Zlotorynski E, Scherer SW, Cheung J, Vincent JB, Smith DI, Trakhtenbrot L, and Kerem B. A role for common fragile site induction in amplification of human oncogenes. *Cancer Cell* 1: 89–97, 2002.
93. Henriksen U, Fog JU, Litman T, and Gether U. Identification of intra- and intermolecular disulfide bridges in the multidrug resistance transporter ABCG2. *J Biol Chem* 280: 36926–36934, 2005.
94. Hesdorffer C, Ayello J, Ward M, Kaubisch A, Vahdat L, Balmaceda C, Garrett T, Fetell M, Reiss R, Bank A, and Antman K. Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation. *J Clin Oncol* 16: 165–172, 1998.
95. Higgins CF. Multiple molecular mechanisms for multidrug resistance transporters. *Nature* 446: 749–757, 2007.
96. Ho MM, Hogge DE, and Ling V. MDR1 and BCRP1 expression in leukemic progenitors correlates with chemotherapy response in acute myeloid leukemia. *Exp Hematol* 36: 433–442, 2008.
97. Ho MM, Ng AV, Lam S, and Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. *Cancer Res* 67: 4827–4833, 2007.
98. Holst B, Tachibana C, and Winther JR. Active site mutations in yeast protein disulfide isomerase cause dithiothreitol sensitivity and a reduced rate of protein folding in the endoplasmic reticulum. *J Cell Biol* 138: 1229–1238, 1997.
99. Hon WC, Wilson MI, Harlos K, Claridge TD, Schofield CJ, Pugh CW, Maxwell PH, Ratcliffe PJ, Stuart DI, and Jones EY. Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL. *Nature* 417: 975–978, 2002.
100. Houghton PJ, Germain GS, Harwood FC, Schuetz JD, Stewart CF, Buchdunger E, and Traxler P. Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. *Cancer Res* 64: 2333–2337, 2004.
101. Huang HC, Nguyen T, and Pickett CB. Regulation of the antioxidant response element by protein kinase C-mediated phosphorylation of NF-E2-related factor 2. *Proc Natl Acad Sci U S A* 97: 12475–12480, 2000.
102. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ, and Abraham RT. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. *Mol Cell Biol* 22: 7004–7014, 2002.
103. Hwang C, Sinskey AJ, and Lodish HF. Oxidized redox state of glutathione in the endoplasmic reticulum. *Science (New York)* 257: 1496–1502, 1992.
104. Hyrien O, Debatisse M, Buttin G, and de SV. The multicopy appearance of a large inverted duplication and the sequence at the inversion joint suggest a new model for gene amplification. *EMBO J* 7: 407–417, 1988.
105. Ichijo H, Nishida E, Irie K, ten DP, Saitoh M, Moriguchi T, Takagi M, Matsumoto K, Miyazono K, and Gotoh Y. In-

- duction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways. *Science* (New York) 275: 90–94, 1997.
106. Ikegami Y, Tatebe S, Lin-Lee YC, Xie QW, Ishikawa T, and Kuo MT. Induction of MRP1 and gamma-glutamylcysteine synthetase gene expression by interleukin 1beta is mediated by nitric oxide-related signalings in human colorectal cancer cells. *J Cell Physiol* 185: 293–301, 2000.
107. Ishikawa K, Takenaga K, Akimoto M, Koshikawa N, Yamaguchi A, Imanishi H, Nakada K, Honma Y, and Hayashi J. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. *Science* (New York) 320: 661–664, 2008.
108. Ishikawa T. The ATP-dependent glutathione S-conjugate export pump. *Trends Biochem Sci* 17: 463–468, 1992.
109. Ishikawa T, Bao JJ, Yamane Y, Akimaru K, Frindrich K, Wright CD, and Kuo MT. Coordinated induction of MRP/GS-X pump and gamma-glutamylcysteine synthetase by heavy metals in human leukemia cells. *J Biol Chem* 271: 14981–14988, 1996.
110. Ito K, Hirao A, Arai F, Matsuoaka S, Takubo K, Hamaguchi I, Nomiyama K, Hosokawa K, Sakurada K, Nakagata N, Ikeda Y, Mak TW, and Suda T. Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. *Nature* 431: 997–1002, 2004.
111. Ito K, Hirao A, Arai F, Takubo K, Matsuoaka S, Miyamoto K, Ohmura M, Naka K, Hosokawa K, Ikeda Y, and Suda T. Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. *Nat Med* 12: 446–451, 2006.
112. Itoh K, Wakabayashi N, Katoh Y, Ishii T, Igarashi K, Engel JD, and Yamamoto M. Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain. *Genes Dev* 13: 76–86, 1999.
113. Jedlitschky G, Leier I, Buchholz U, Center M, and Keppler D. ATP-dependent transport of glutathione S-conjugates by the multidrug resistance-associated protein. *Cancer Res* 54: 4833–4836, 1994.
114. Jin S and Scotto KW. Transcriptional regulation of the MDR1 gene by histone acetyltransferase and deacetylase is mediated by NF-Y. *Mol Cell Biol* 18: 4377–4384, 1998.
115. Jonker JW, Buitelaar M, Wagenaar E, van de V, Scheffer GL, Scheper RJ, Plosch T, Kuipers F, Elferink RP, Rosing H, Beijnen JH, and Schinkel AH. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. *Proc Natl Acad Sci U S A* 99: 15649–15654, 2002.
116. Kaelin WG Jr. ROS: really involved in oxygen sensing. *Cell Metab* 1: 357–358, 2005.
117. Kage K, Fujita T, and Sugimoto Y. Role of Cys-603 in dimer/oligomer formation of the breast cancer resistance protein BCRP/ABCG2. *Cancer Sci* 96: 866–872, 2005.
118. Karanjawala ZE, Murphy N, Hinton DR, Hsieh CL, and Lieber MR. Oxygen metabolism causes chromosome breaks and is associated with the neuronal apoptosis observed in DNA double-strand break repair mutants. *Curr Biol* 12: 397–402, 2002.
119. Karin M, Cao Y, Greten FR, and Li ZW. NF-kappaB in cancer: from innocent bystander to major culprit. *Nat Rev Cancer* 2: 301–310, 2002.
120. Kartenbeck J, Leuschner U, Mayer R, and Keppler D. Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome. *Hepatology* 23: 1061–1066, 1996.
121. Karwatsky J, Leimanis M, Cai J, Gros P, and Georges E. The leucotriene C4 binding sites in multidrug resistance protein 1 (ABCC1) include the first membrane multiple spanning domain. *Biochemistry* 44: 340–351, 2005.
122. Kauffmann HM, Pfannschmidt S, Zoller H, Benz A, Vorderstemann B, Webster JL, and Schrenk D. Influence of redox-active compounds and PXR-activators on human MRP1 and MRP2 gene expression. *Toxicology* 171: 137–146, 2002.
123. Kawahara BT, Quinn MT, and Lambeth JD. Molecular evolution of the reactive oxygen-generating NADPH oxidase (Nox/Duox) family of enzymes. *Br Med C Evol Biol* 7: 109, 2007.
124. Keshet GI, Goldstein I, Yitzhaki O, Cesarkas K, Shenhav L, Yakirevitch A, Treves AJ, Schachter J, Amariglio N, and Rechavi G. MDR1 expression identifies human melanoma stem cells. *Biochem Biophys Res Commun* 2008.
125. Kim M, Turnquist H, Jackson J, Sgagias M, Yan Y, Gong M, Dean M, Sharp JG, and Cowan K. The multidrug resistance transporter ABCG2 (breast cancer resistance protein 1) effluxes Hoechst 33342 and is overexpressed in hematopoietic stem cells. *Clin Cancer Res* 8: 22–28, 2002.
126. Klement JF, Matsuzaki Y, Jiang QJ, Terlizzi J, Choi HY, Fujimoto N, Li K, Pulkkinen L, Birk DE, Sundberg JP, and Uitto J. Targeted ablation of the abcc6 gene results in ectopic mineralization of connective tissues. *Mol Cell Biol* 25: 8299–8310, 2005.
127. Kobayashi A, Kang MI, Watai Y, Tong KI, Shibata T, Uchida K, and Yamamoto M. Oxidative and electrophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1. *Mol Cell Biol* 26: 221–229, 2006.
128. Krishnamurthy P, Ross DD, Nakanishi T, Bailey-Dell K, Zhou S, Mercer KE, Sarkadi B, Sorrentino BP, and Schuetz JD. The stem cell marker BCRP/ABCG2 enhances hypoxic cell survival through interactions with heme. *J Biol Chem* 279: 24218–24225, 2004.
129. Krishnamurthy P and Schuetz JD. Role of ABCG2/BCRP in biology and medicine. *Annu Rev Pharmacol Toxicol* 46: 381–410, 2006.
130. Krishnamurthy P, Xie T, and Schuetz JD. The role of transporters in cellular heme and porphyrin homeostasis. *Pharmacol Ther* 114: 345–358, 2007.
131. Kruh GD and Belinsky MG. The MRP family of drug efflux pumps. *Oncogene* 22: 7537–7552, 2003.
132. Kumar A, Marques M, and Carrera AC. Phosphoinositide 3-kinase activation in late G1 is required for c-Myc stabilization and S phase entry. *Mol Cell Biol* 26: 9116–9125, 2006.
133. Kuo MT. Expression of multidrug-resistance (P-glycoprotein) genes in liver cancers: a molecular example of the convergence theory of hepatocarcinogenesis? *Mol Carcinog* 7: 73–75, 1993.
134. Kuo MT. Roles of multidrug resistance genes in breast cancer chemoresistance. *Adv Exp Med Biol* 608: 23–30, 2007.
135. Kuo MT, Bao J, Furuichi M, Yamane Y, Gomi A, Savaraj N, Masuzawa T, and Ishikawa T. Frequent coexpression of MRP/GS-X pump and gamma-glutamylcysteine synthetase mRNA in drug-resistant cells, untreated tumor cells, and normal mouse tissues. *Biochem Pharmacol* 55: 605–615, 1998.
136. Kuo MT, Bao JJ, Curley SA, Ikeguchi M, Johnston DA, and Ishikawa T. Frequent coordinated overexpression of the MRP/GS-X pump and gamma-glutamylcysteine synthetase genes in human colorectal cancers. *Cancer Res* 56: 3642–3644, 1996.
137. Kuo MT, Liu Z, Wei Y, Lin-Lee YC, Tatebe S, Mills GB, and Unate H. Induction of human MDR1 gene expression by

- 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kapab signaling. *Oncogene* 21: 1945–1954, 2002.
138. Kuo MT, Sen S, Hittelman WN, and Hsu TC. Chromosomal fragile sites and DNA amplification in drug-resistant cells. *Biochem Pharmacol* 56: 7–13, 1998.
139. Kuo MT, Vyas RC, Jiang LX, and Hittelman WN. Chromosome breakage at a major fragile site associated with P-glycoprotein gene amplification in multidrug-resistant CHO cells. *Mol Cell Biol* 14: 5202–5211, 1994.
140. Lambeth JD, Kawahara T, and Diebold B. Regulation of Nox and Duox enzymatic activity and expression. *Free Radic Biol Med* 43: 319–331, 2007.
141. Lambrecht RW, Thapar M, and Bonkovsky HL. Genetic aspects of porphyria cutanea tarda. *Semin Liver Dis* 27: 99–108, 2007.
142. Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J, Minden M, Paterson B, Caligiuri MA, and Dick JE. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. *Nature* 367: 645–648, 1994.
143. Le LH, Moore MJ, Siu LL, Oza AM, MacLean M, Fisher B, Chaudhary A, de Alwis DP, Slapak C, and Seymour L. Phase I study of the multidrug resistance inhibitor zo-suquidar administered in combination with vinorelbine in patients with advanced solid tumours. *Cancer Chemother Pharmacol* 56: 154–160, 2005.
144. Lee JM, Hanson JM, Chu WA, and Johnson JA. Phosphatidylinositol 3-kinase, not extracellular signal-regulated kinase, regulates activation of the antioxidant-responsive element in IMR-32 human neuroblastoma cells. *J Biol Chem* 276: 20011–20016, 2001.
145. Leggas M, Adachi M, Scheffer GL, Sun D, Wielinga P, Du G, Mercer KE, Zhuang Y, Panetta JC, Johnston B, Scheper RJ, Stewart CF, and Schuetz JD. Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. *Mol Cell Biol* 24: 7612–7621, 2004.
146. Legouy E, Fossar N, Lhomond G, and Brison O. Structure of four amplified DNA novel joints. *Somat Cell Mol Genet* 15: 309–320, 1989.
147. Leier I, Jedlitschky G, Buchholz U, Center M, Cole SP, Deeley RG, and Keppler D. ATP-dependent glutathione disulphide transport mediated by the MRP gene-encoded conjugate export pump. *Biochem J* 314: 433–437, 1996.
148. Leier I, Jedlitschky G, Buchholz U, Cole SP, Deeley RG, and Keppler D. The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. *J Biol Chem* 269: 27807–27810, 1994.
149. Leonard GD, Fojo T, and Bates SE. The role of ABC transporters in clinical practice. *Oncologist* 8: 411–424, 2003.
150. Lertratanangkoon K, Wu CJ, Savaraj N, and Thomas ML. Alterations of DNA methylation by glutathione depletion. *Cancer Lett* 120: 149–156, 1997.
151. Leslie EM, Bowers RJ, Deeley RG, and Cole SP. Structural requirements for functional interaction of glutathione tripeptide analogs with the human multidrug resistance protein 1 (MRP1). *J Pharmacol Exp Ther* 304: 643–653, 2003.
152. Leslie EM, Ito K, Upadhyaya P, Hecht SS, Deeley RG, and Cole SP. Transport of the beta-O-glucuronide conjugate of the tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by the multidrug resistance protein 1 (MRP1): requirement for glutathione or a non-sulfur-containing analog. *J Biol Chem* 276: 27846–27854, 2001.
153. Leslie EM, Letourneau IJ, Deeley RG, and Cole SP. Functional and structural consequences of cysteine substitutions in the NH2 proximal region of the human multidrug resistance protein 1 (MRP1/ABCC1). *Biochemistry* 42: 5214–5224, 2003.
154. Levine AJ, Hu W, and Feng Z. The P53 pathway: what questions remain to be explored? *Cell Death Differ* 13: 1027–1036, 2006.
155. Lin-Lee YC, Tatebe S, Savaraj N, Ishikawa T, and Tien KM. Differential sensitivities of the MRP gene family and gamma-glutamylcysteine synthetase to prooxidants in human colorectal carcinoma cell lines with different p53 status. *Biochem Pharmacol* 61: 555–563, 2001.
156. Liu B, Chen Y, and St Clair DK. ROS and p53: a versatile partnership. *Free Radic Biol Med* 44: 1529–1535, 2008.
157. Liu M, Li D, Aneja R, Joshi HC, Xie S, Zhang C, and Zhou J. PO(2)-dependent differential regulation of multidrug resistance 1 gene expression by the c-Jun NH2-terminal kinase pathway. *J Biol Chem* 282: 17581–17586, 2007.
158. Liu Y, Yang Y, Qi J, Peng H, and Zhang JT. Effect of cysteine mutagenesis on the function and disulfide bond formation of human ABCG2. *J Pharmacol Exp Ther* 326: 33–40, 2008.
159. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, and Tlsty TD. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. *Cell* 70: 923–935, 1992.
160. Lo AW, Sprung CN, Fouladi B, Pedram M, Sabatier L, Ricoul M, Reynolds GE, and Murnane JP. Chromosome instability as a result of double-strand breaks near telomeres in mouse embryonic stem cells. *Mol Cell Biol* 22: 4836–4850, 2002.
161. Lobo NA, Shimono Y, Qian D, and Clarke MF. The biology of cancer stem cells. *Annu Rev Cell Dev Biol* 23: 675–699, 2007.
162. Loe DW, Deeley RG, and Cole SP. Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. *Cancer Res* 58: 5130–5136, 1998.
163. Lopez dSI, Fan J, Yang X, Zonderman AB, Potapova O, Pizer ES, and Gorospe M. Role of the RNA-binding protein HuR in colon carcinogenesis. *Oncogene* 22: 7146–7154, 2003.
164. Luedde T, Beraza N, Kotsikoros V, van Loo G, Nenci A, De Vos R, Roskams T, Trautwein C, and Pasparakis M. Deletion of NEMO/IKKgamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma1. *Cancer Cell* 11: 119–132, 2007.
165. Luftig M, Yasui T, Soni V, Kang MS, Jacobson N, Cahir-McFarland E, Seed B, and Kieff E. Epstein-Barr virus latent infection membrane protein 1 TRAF-binding site induces NIK/IKK alpha-dependent noncanonical NF-kappaB activation. *Proc Natl Acad Sci U S A* 101: 141–146, 2004.
166. Manciu L, Chang XB, Buyse F, Hou YX, Gustot A, Riordan JR, and Ruysschaert JM. Intermediate structural states involved in MRP1-mediated drug transport: role of glutathione. *J Biol Chem* 278: 3347–3356, 2003.
167. Mankhetkorn S, Dubru F, Hesschenbrouck J, Fiallo M, and Garnier-Suillerot A. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells. *Mol Pharmacol* 49: 532–539, 1996.
168. Manohar CF, Bray JA, Salwen HR, Madafiglio J, Cheng A, Flemming C, Marshall GM, Norris MD, Haber M, and Cohn SL. MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma. *Oncogene* 23: 753–762, 2004.

169. Mansfield KD, Guzy RD, Pan Y, Young RM, Cash TP, Schumacker PT, and Simon MC. Mitochondrial dysfunction resulting from loss of cytochrome c impairs cellular oxygen sensing and hypoxic HIF- α activation. *Cell Metab* 1: 393–399, 2005.
170. Matsuzawa A and Ichijo H. Redox control of cell fate by MAP kinase: physiological roles of ASK1–MAP kinase pathway in stress signaling. *Biochim Biophys Acta* 2008.
171. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, and Franklin RA. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. *Biochim Biophys Acta* 1773: 1263–1284, 2007.
172. Mei Y, Wei D, and Liu J. Reversal of multidrug resistance in KB cells with tea polyphenol antioxidant capacity. *Cancer Biol Ther* 4: 468–473, 2005.
173. Messersmith WA, Hidalgo M, Carducci M, and Eckhardt SG. Novel targets in solid tumors: MEK inhibitors. *Clin Adv Hematol Oncol* 4: 831–836, 2006.
174. Meyers MB, Spengler BA, Chang TD, Melera PW, and Biedler JL. Gene amplification-associated cytogenetic aberrations and protein changes in vincristine-resistant Chinese hamster, mouse, and human cells. *J Cell Biol* 100: 588–597, 1985.
175. Miller JR, Hocking AM, Brown JD, and Moon RT. Mechanism and function of signal transduction by the Wnt/ β -catenin and Wnt/ Ca^{2+} pathways. *Oncogene* 18: 7860–7872, 1999.
176. Minderman H, Zhou Y, O'Loughlin KL, and Baer MR. Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status. *Cancer Chemother Pharmacol* 60: 245–255, 2007.
177. Miura K, Yoshiura K, Miura S, Shimada T, Yamasaki K, Yoshida A, Nakayama D, Shibata Y, Niikawa N, and Masuzaki H. A strong association between human earwax-type and apocrine colostrum secretion from the mammary gland. *Hum Genet* 121: 631–633, 2007.
178. Miyake K, Mickley L, Litman T, Zhan Z, Robey R, Cristensen B, Brangi M, Greenberger L, Dean M, Fojo T, and Bates SE. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. *Cancer Res* 59: 8–13, 1999.
179. Mogi M, Yang J, Lambert JF, Colvin GA, Shiojima I, Skurk C, Summer R, Fine A, Quesenberry PJ, and Walsh K. Akt signaling regulates side population cell phenotype via Bcrp1 translocation. *J Biol Chem* 278: 39068–39075, 2003.
180. Molnar J, Gyemant N, Tanaka M, Hohmann J, Bergmann-Leitner E, Molnar P, Deli J, Didiziapetris R, and Ferreira MJ. Inhibition of multidrug resistance of cancer cells by natural diterpenes, triterpenes and carotenoids. *Curr Pharm Des* 12: 287–311, 2006.
181. Moscow JA, Huang H, Carter C, Hines K, Zujewski J, Cusack G, Chow C, Venzon D, Sorrentino B, Chiang Y, Goldspiel B, Leitman S, Read EJ, Abati A, Gottesman MM, Pastan I, Sellers S, Dunbar C, and Cowan KH. Engraftment of MDR1 and NeoR gene-transduced hematopoietic cells after breast cancer chemotherapy. *Blood* 94: 52–61, 1999.
182. Mossink MH, van Zon A, Franzel-Luiten E, Schoester M, Kickhoefer VA, Scheffer GL, Scheper RJ, Sonneveld P, and Wiemer EA. Disruption of the murine major vault protein (MVP/LRP) gene does not induce hypersensitivity to cytostatics. *Cancer Res* 62: 7298–7304, 2002.
183. Mossink MH, van Zon A, Scheper RJ, Sonneveld P, and Wiemer EA. Vaults: a ribonucleoprotein particle involved in drug resistance? *Oncogene* 22: 7458–7467, 2003.
184. Muller M, Meijer C, Zaman GJ, Borst P, Scheper RJ, Mulder NH, De Vries EG, and Jansen PL. Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. *Proc Natl Acad Sci U S A* 91: 13033–13037, 1994.
185. Narasimhaiah R, Tuchman A, Lin SL, and Naegele JR. Oxidative damage and defective DNA repair is linked to apoptosis of migrating neurons and progenitors during cerebral cortex development in Ku70-deficient mice. *Cereb Cortex* 15: 696–707, 2005.
186. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, and Karin M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. *Science (New York)* 317: 121–124, 2007.
187. Nguyen T, Sherratt PJ, Nioi P, Yang CS, and Pickett CB. Nrf2 controls constitutive and inducible expression of ARE-driven genes through a dynamic pathway involving nucleocytoplasmic shuttling by Keap1. *J Biol Chem* 280: 32485–32492, 2005.
188. Nguyen T, Yang CS, and Pickett CB. The pathways and molecular mechanisms regulating Nrf2 activation in response to chemical stress. *Free Radic Biol Med* 37: 433–441, 2004.
189. Nobili S, Landini I, Giglioni B, and Mini E. Pharmacological strategies for overcoming multidrug resistance. *Curr Drug Targets* 7: 861–879, 2006.
190. O'Brien CA, Pollett A, Gallinger S, and Dick JE. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. *Nature* 445: 106–110, 2007.
191. Okuno Y, Hahn PJ, and Gilbert DM. Structure of a palindromic amplicon junction implicates microhomology-mediated end joining as a mechanism of sister chromatid fusion during gene amplification. *Nucleic Acids Res* 32: 749–756, 2004.
192. Ono N, Van dHI, Scheffer GL, van de WK, Van DE, de HM, Boerke A, Gadella BM, De Rooij DG, Neeffes JJ, Groothuis TA, Oomen L, Brocks L, Ishikawa T, and Borst P. Multidrug resistance-associated protein 9 (ABCC12) is present in mouse and boar sperm. *Biochem J* 406: 31–40, 2007.
193. Ozvegy-Laczka C, Hegedus T, Varady G, Ujhelly O, Schuetz JD, Varadi A, Keri G, Orfi L, Nemet K, and Sarkadi B. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. *Mol Pharmacol* 65: 1485–1495, 2004.
194. Papenhausen PR, Griffin S, and Tepperberg J. Oncogene amplification in transforming myelodysplasia. *Exp Mol Pathol* 79: 168–175, 2005.
195. Pham CG, Bubici C, Zazzeroni F, Knabb JR, Papa S, Kuntzen C, and Franzoso G. Upregulation of twist-1 by NF- κ B blocks cytotoxicity induced by chemotherapeutic drugs. *Mol Cell Biol* 27: 3920–3935, 2007.
196. Pham CG, Bubici C, Zazzeroni F, Papa S, Jones J, Alvarez K, Jayawardena S, De Smaele E, Cong R, Beaumont C, Torti FM, Torti SV, and Franzoso G. Ferritin heavy chain upregulation by NF- κ B inhibits TNF α -induced apoptosis by suppressing reactive oxygen species. *Cell* 119: 529–542, 2004.
197. Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, and Ben-Neriah Y. NF- κ B functions as a tumour promoter in inflammation-associated cancer. *Nature* 431: 461–466, 2004.

198. Pirker R, Wallner J, Geissler K, Linkesch W, Haas OA, Bettelheim P, Hopfner M, Scherrer R, Valent P, Havelec L, Ludwig H, and Lechner K. MDR1 gene expression and treatment outcome in acute myeloid leukemia. *J Natl Cancer Inst* 83: 708–712, 1991.
199. Planting AS, Sonneveld P, van der GA, Sparreboom A, van der Burg ME, Luyten GP, de LK, de Boer-Dennert M, Wissel PS, Jewell RC, Paul EM, Purvis NB Jr, and Verweij J. A phase I and pharmacologic study of the MDR converter GF120918 in combination with doxorubicin in patients with advanced solid tumors. *Cancer Chemother Pharmacol* 55: 91–99, 2005.
200. Plasschaert SL, de Bont ES, Boezen M, vander Kolk DM, Daenen SM, Faber KN, Kamps WA, de Vries EG, and Vellenga E. Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia. *Clin Cancer Res* 11: 8661–8668, 2005.
201. Pouyssegur J and Mechta-Grigoriou F. Redox regulation of the hypoxia-inducible factor. *Biol Chem* 387: 1337–1346, 2006.
202. Powis G and Kirkpatrick L. Hypoxia inducible factor-1alpha as a cancer drug target. *Mol Cancer Ther* 3: 647–654, 2004.
203. Qian YM, Grant CE, Westlake CJ, Zhang DW, Lander PA, Shepard RL, Dantzig AH, Cole SP, and Deeley RG. Photolabeling of human and murine multidrug resistance protein 1 with the high affinity inhibitor [125I]LY475776 and azidophenacyl-[³⁵S]glutathione. *J Biol Chem* 277: 35225–35231, 2002.
204. Randle RA, Raguz S, Higgins CF, and Yague E. Role of the highly structured 5'-end region of MDR1 mRNA on P-glycoprotein expression. *Biochem J* 406: 445–455, 2007.
205. Ravi D, Muniyappa H, and Das KC. Endogenous thioredoxin is required for redox cycling of anthracyclines and p53-dependent apoptosis in cancer cells. *J Biol Chem* 280: 40084–40096, 2005.
206. Reid G, Wielinga P, Zelcer N, de HM, van DL, Wijnholds J, Balzarini J, and Borst P. Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. *Mol Pharmacol* 63: 1094–1103, 2003.
207. Reliene R, Fischer E, and Schiestl RH. Effect of N-acetyl cysteine on oxidative DNA damage and the frequency of DNA deletions in atm-deficient mice. *Cancer Res* 64: 5148–5153, 2004.
208. Reliene R, Goad ME, and Schiestl RH. Developmental cell death in the liver and newborn lethality of Ku86 deficient mice suppressed by antioxidant N-acetyl-cysteine. *DNA Repair (Amst)* 5: 1392–1397, 2006.
209. Ren XQ, Furukawa T, Nakajima Y, Takahashi H, Aoki S, Sumizawa T, Haraguchi M, Kobayashi M, Chijiwa K, and Akiyama S. GSH inhibits trypsinization of the C-terminal half of human MRP1. *J Biol Chem* 280: 6231–6237, 2005.
210. Renes J, de Vries EG, Nienhuis EF, Jansen PL, and Muller M. ATP- and glutathione-dependent transport of chemotherapeutic drugs by the multidrug resistance protein MRP1. *Br J Pharmacol* 126: 681–688, 1999.
211. Rice GC, Hoy C, and Schimke RT. Transient hypoxia enhances the frequency of dihydrofolate reductase gene amplification in Chinese hamster ovary cells. *Proc Natl Acad Sci U S A* 83: 5978–5982, 1986.
212. Rich JN. Cancer stem cells in radiation resistance. *Cancer Res* 67: 8980–8984, 2007.
213. Ristoff E, Augustson C, Geissler J, de RT, Carlsson K, Luo JL, Andersson K, Weening RS, van ZR, Larsson A, and Roos D. A missense mutation in the heavy subunit of gamma-glutamylcysteine synthetase gene causes hemolytic anemia. *Blood* 95: 2193–2196, 2000.
214. Robey RW, Polgar O, Deeken J, To KW, and Bates SE. ABCG2: determining its relevance in clinical drug resistance. *Cancer Metastasis Rev* 26: 39–57, 2007.
215. Robey RW, Steadman K, Polgar O, Morisaki K, Blayney M, Mistry P, and Bates SE. Pheophorbide a is a specific probe for ABCG2 function and inhibition. *Cancer Res* 64: 1242–1246, 2004.
216. Robey RW, Zhan Z, Piekarczyk RL, Kayastha GL, Fojo T, and Bates SE. Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving desisipeptide (FR901228, FK228, NSC630176). *Clin Cancer Res* 12: 1547–1555, 2006.
217. Rozan LM and El-Deiry WS. p53 downstream target genes and tumor suppression: a classical view in evolution. *Cell Death Differ* 14: 3–9, 2007.
218. Rumpold H, Salvador C, Wolf AM, Tilg H, Gastl G, and Wolf D. Knockdown of P-gp resensitizes leukemic cells to proteasome inhibitors. *Biochem Biophys Res Commun* 361: 549–554, 2007.
219. Salerno M and Garnier-Suillerot A. Kinetics of glutathione and daunorubicin efflux from multidrug resistance protein overexpressing small-cell lung cancer cells. *Eur J Pharmacol* 421: 1–9, 2001.
220. Salerno M, Loechariyakul P, Saengkhae C, and Garnier-Suillerot A. Relation between the ability of some compounds to modulate the MRP1-mediated efflux of glutathione and to inhibit the MRP1-mediated efflux of daunorubicin. *Biochem Pharmacol* 68: 2159–2165, 2004.
221. Sampath J, Adachi M, Hatse S, Naesens L, Balzarini J, Flatley RM, Matherly LH, and Schuetz JD. Role of MRP4 and MRP5 in biology and chemotherapy. *AAPS Pharm Sci* 4: E14, 2002.
222. Scharenberg CW, Harkey MA, and Torok-Storb B. The ABCG2 transporter is an efficient Hoechst 33342 efflux pump and is preferentially expressed by immature human hematopoietic progenitors. *Blood* 99: 507–512, 2002.
223. Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, Zhan Q, Jordan S, Duncan LM, Weishaupt C, Fuhlbrigge RC, Kupper TS, Sayegh MH, and Frank MH. Identification of cells initiating human melanomas. *Nature* 451: 345–349, 2008.
224. Scheffer GL, Wijngaard PL, Flens MJ, Izquierdo MA, Slovak ML, Pinedo HM, Meijer CJ, Clevers HC, and Scheper RJ. The drug resistance-related protein LRP is the human major vault protein. *Nat Med* 1: 578–582, 1995.
225. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, van der Valk MA, Voordouw AC, Spits H, van Tellingen O, Zijlmans JM, Fibbe WE, and Borst P. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. *Proc Natl Acad Sci U S A* 94: 4028–4033, 1997.
226. Schinkel AH, Mol CA, Wagenaar E, van DL, Smit JJ, and Borst P. Multidrug resistance and the role of P-glycoprotein knockout mice. *Eur J Cancer* 31A: 1295–1298, 1995.
227. Schoenlein PV, Shen DW, Barrett JT, Pastan I, and Gottesman MM. Double minute chromosomes carrying the human multidrug resistance 1 and 2 genes are generated from the dimerization of submicroscopic circular DNAs in colchicine-selected KB carcinoma cells. *Mol Biol Cell* 3: 507–520, 1992.
228. Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, Srinivas RV, Kumar A, and Fridland A. MRP4: A pre-

- ously unidentified factor in resistance to nucleoside-based antiviral drugs. *Nat Med* 5: 1048–1051, 1999.
229. Scotto KW. Transcriptional regulation of ABC drug transporters. *Oncogene* 22: 7496–7511, 2003.
230. Seemann S and Hainaut P. Roles of thioredoxin reductase 1 and APE/Ref-1 in the control of basal p53 stability and activity. *Oncogene* 24: 3853–3863, 2005.
231. Sekhar KR, Soltaninassab SR, Borrelli MJ, Xu ZQ, Meredith MJ, Domann FE, and Freeman ML. Inhibition of the 26S proteasome induces expression of GLCLC, the catalytic subunit for gamma-glutamylcysteine synthetase. *Biochem Biophys Res Commun* 270: 311–317, 2000.
232. Sellers SE, Tisdale JF, Agricola BA, Metzger ME, Donahue RE, Dunbar CE, and Sorrentino BP. The effect of multidrug-resistance 1 gene versus neo transduction on ex vivo and in vivo expansion of rhesus macaque hematopoietic repopulating cells. *Blood* 97: 1888–1891, 2001.
233. Semenza GL. Evaluation of HIF-1 inhibitors as anticancer agents. *Drug Discov Today* 12: 853–859, 2007.
234. Semenza GL. Hypoxia and human disease. *J Mol Med* 85: 1293–1294, 2007.
235. Semenza GL. Targeting HIF-1 for cancer therapy. *Nat Rev Cancer* 3: 721–732, 2003.
236. Sevier CS, Qu H, Heldman N, Gross E, Fass D, and Kaiser CA. Modulation of cellular disulfide-bond formation and the ER redox environment by feedback regulation of Ero1. *Cell* 129: 333–344, 2007.
237. Sharma R, Yang Y, Sharma A, Awasthi S, and Awasthi YC. Antioxidant role of glutathione S-transferases: protection against oxidant toxicity and regulation of stress-mediated apoptosis. *Antioxid Redox Signal* 6: 289–300, 2004.
238. Shuster MI, Han L, Le Beau MM, Davis E, Sawicki M, Lese CM, Park NH, Colicelli J, and Gollin SM. A consistent pattern of RIN1 rearrangements in oral squamous cell carcinoma cell lines supports a breakage-fusion-bridge cycle model for 11q13 amplification. *Genes Chromosomes Cancer* 28: 153–163, 2000.
239. Sims-Mourtada J, Izzo JG, Ajani J, and Chao KS. Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport. *Oncogene* 26: 5674–5679, 2007.
240. Slovak ML, Ho JP, Cole SP, Deeley RG, Greenberger L, de Vries EG, Broxterman HJ, Scheffer GL, and Scheper RJ. The LRP gene encoding a major vault protein associated with drug resistance maps proximal to MRP on chromosome 16: evidence that chromosome breakage plays a key role in MRP or LRP gene amplification. *Cancer Res* 55: 4214–4219, 1995.
241. Smalley MJ and Clarke RB. The mammary gland “side population”: a putative stem/progenitor cell marker? *J Mammary Gland Biol Neoplasia* 10: 37–47, 2005.
242. Song IS, Tatebe S, Dai W, and Kuo MT. Delayed mechanism for induction of gamma-glutamylcysteine synthetase heavy subunit mRNA stability by oxidative stress involving p38 mitogen-activated protein kinase signaling. *J Biol Chem* 280: 28230–28240, 2005.
243. Sprung CN, Reynolds GE, Jasin M, and Murnane JP. Chromosome healing in mouse embryonic stem cells. *Proc Natl Acad Sci U S A* 96: 6781–6786, 1999.
244. Styczynski J, Wysocki M, Debski R, Czyzewski K, Kolodziej B, Rafinska B, Kubicka M, Koltan S, Koltan A, Pogorzala M, Kurylak A, Olszewska-Slonina D, Balwierz W, Juraszewska E, Wiczorek M, Olejnik I, Krawczuk-Rybak M, Kuzmich M, Kowalczyk J, Stefaniak J, Badowska W, Sonta-Jakimczyk D, Szczepanski T, Matysiak M, Malinowska I, Stanczak E, Wachowiak J, Konatkowska B, Gil L, Balcerska A, and Maciejka-Kapuscinska L. Predictive value of multidrug resistance proteins and cellular drug resistance in childhood relapsed acute lymphoblastic leukemia. *J Cancer Res Clin Oncol* 133: 875–893, 2007.
245. Szatmari I, Vamosi G, Brazda P, Balint BL, Benko S, Szeles L, Jeney V, Ozvegy-Laczka C, Szanto A, Barta E, Balla J, Sarkadi B, and Nagy L. Peroxisome proliferator-activated receptor gamma-regulated ABCG2 expression confers cytoprotection to human dendritic cells. *J Biol Chem* 281: 23812–23823, 2006.
246. Szotek PP, Pieretti-Vanmarcke R, Masiakos PT, Dinulescu DM, Connolly D, Foster R, Dombkowski D, Preffer F, Maclaughlin DT, and Donahoe PK. Ovarian cancer side population defines cells with stem cell-like characteristics and mullerian inhibiting substance responsiveness. *Proc Natl Acad Sci U S A* 103: 11154–11159, 2006.
247. Takada T, Suzuki H, Gotoh Y, and Sugiyama Y. Regulation of the cell surface expression of human BCRP/ABCG2 by the phosphorylation state of Akt in polarized cells. *Drug Metab Dispos* 33: 905–909, 2005.
248. Takahashi-Yanaga F and Sasaguri T. The Wnt/beta-catenin signaling pathway as a target in drug discovery. *J Pharmacol Sci* 104: 293–302, 2007.
249. Takara K, Sakaeda T, and Okumura K. An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. *Curr Pharm Des* 12: 273–286, 2006.
250. Tanaka T, Uchiumi T, Hinoshita E, Inokuchi A, Toh S, Wada M, Takano H, Kohno K, and Kuwano M. The human multidrug resistance protein 2 gene: functional characterization of the 5'-flanking region and expression in hepatic cells. *Hepatology* 30: 1507–1512, 1999.
251. Tatebe S, Unate H, Sinicrope FA, Sakatani T, Sugamura K, Makino M, Ito H, Savaraj N, Kaibara N, and Kuo MT. Expression of heavy subunit of gamma-glutamylcysteine synthetase (gamma-GCSH) in human colorectal carcinoma. *Int J Cancer* 97: 21–27, 2002.
252. Taylor CT. Mitochondria and cellular oxygen sensing in the HIF pathway. *Biochem J* 409: 19–26, 2008.
253. Teeter LD, Atsumi S, Sen S, and Kuo T. DNA amplification in multidrug, cross-resistant Chinese hamster ovary cells: molecular characterization and cytogenetic localization of the amplified DNA. *J Cell Biol* 103: 1159–1166, 1986.
254. Teeter LD, Becker FF, Chisari FV, Li DJ, and Kuo MT. Overexpression of the multidrug resistance gene mdr3 in spontaneous and chemically induced mouse hepatocellular carcinomas. *Mol Cell Biol* 10: 5728–5735, 1990.
255. Teeter LD, Estes M, Chan JY, Atassi H, Sell S, Becker FF, and Kuo MT. Activation of distinct multidrug-resistance (P-glycoprotein) genes during rat liver regeneration and hepatocarcinogenesis. *Mol Carcinog* 8: 67–73, 1993.
256. Tien KM and Savaraj N. Roles of reactive oxygen species in hepatocarcinogenesis and drug resistance gene expression in liver cancers. *Mol Carcinog* 45: 701–709, 2006.
257. Tlsty TD, Brown PC, and Schimke RT. UV radiation facilitates methotrexate resistance and amplification of the dihydrofolate reductase gene in cultured 3T6 mouse cells. *Mol Cell Biol* 4: 1050–1056, 1984.
258. To KK, Polgar O, Huff LM, Morisaki K, and Bates SE. Histone modifications at the ABCG2 promoter following treatment with histone deacetylase inhibitor mirror those in multidrug-resistant cells. *Mol Cancer Res* 6: 151–164, 2008.
259. Toledo F, Le RD, Buttin G, and Debatisse M. Co-amplified markers alternate in megabase long chromosomal inverted repeats and cluster independently in interphase nuclei at

- early steps of mammalian gene amplification. *EMBO J* 11: 2665–2673, 1992.
260. Tothova Z, Kollipara R, Huntly BJ, Lee BH, Castrillon DH, Cullen DE, McDowell EP, Lazo-Kallanian S, Williams IR, Sears C, Armstrong SA, Passegue E, DePinho RA, and Gilliland DG. FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. *Cell* 128: 325–339, 2007.
 261. Triantafyllou A, Liakos P, Tsakalof A, Georgatsou E, Simos G, and Bonanou S. Cobalt induces hypoxia-inducible factor-1 α (HIF-1 α) in HeLa cells by an iron-independent, but ROS-, PI-3K- and MAPK-dependent mechanism. *Free Radic Res* 40: 847–856, 2006.
 262. Tu BP and Weissman JS. Oxidative protein folding in eukaryotes: mechanisms and consequences. *J Cell Biol* 164: 341–346, 2004.
 263. Vafa O, Wade M, Kern S, Beeche M, Pandita TK, Hampton GM, and Wahl GM. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. *Mol Cell* 9: 1031–1044, 2002.
 264. Valinluck V, Tsai HH, Rogstad DK, Burdzy A, Bird A, and Sowers LC. Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2). *Nucleic Acids Res* 32: 4100–4108, 2004.
 265. van der Kolk DM, de Vries EG, Muller M, and Vellenga E. The role of drug efflux pumps in acute myeloid leukemia. *Leukemia Lymphoma* 43: 685–701, 2002.
 266. Van Waes C. Nuclear factor-kappaB in development, prevention, and therapy of cancer. *Clin Cancer Res* 13: 1076–1082, 2007.
 267. Velu CS, Niture SK, Doneanu CE, Pattabiraman N, and Srivenugopal KS. Human p53 is inhibited by glutathionylation of cysteines present in the proximal DNA-binding domain during oxidative stress. *Biochemistry* 46: 7765–7780, 2007.
 268. Versantvoort CH, Broxterman HJ, Bagrij T, Scheper RJ, and Twentyman PR. Regulation by glutathione of drug transport in multidrug-resistant human lung tumour cell lines overexpressing multidrug resistance-associated protein. *Br J Cancer* 72: 82–89, 1995.
 269. Vollrath V, Wielandt AM, Iruretagoyena M, and Chianale J. Role of Nrf2 in the regulation of the Mrp2 (ABCC2) gene. *Biochem J* 395: 599–609, 2006.
 270. Wakabayashi K, Nakagawa H, Adachi T, Kii I, Kobatake E, Kudo A, and Ishikawa T. Identification of cysteine residues critically involved in homodimer formation and protein expression of human ATP-binding cassette transporter ABCG2: a new approach using the flp recombinase system. *J Exp Ther Oncol* 5: 205–222, 2006.
 271. Wakabayashi K, Tamura A, Saito H, Onishi Y, and Ishikawa T. Human ABC transporter ABCG2 in xenobiotic protection and redox biology. *Drug Metab Rev* 38: 371–391, 2006.
 272. Wallace-Brodeur RR and Lowe SW. Clinical implications of p53 mutations. *Cell Mol Life Sci* 55: 64–75, 1999.
 273. Welsh SJ, Williams RR, Birmingham A, Newman DJ, Kirkpatrick DL, and Powis G. The thioredoxin redox inhibitors 1-methylpropyl 2-imidazolyl disulfide and pleurotin inhibit hypoxia-induced factor 1 α and vascular endothelial growth factor formation. *Mol Cancer Ther* 2: 235–243, 2003.
 274. Wijnholds J, Evers R, van Leusden MR, Mol CA, Zaman GJ, Mayer U, Beijnen JH, van dV, Krimpenfort P, and Borst P. Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. *Nat Med* 3: 1275–1279, 1997.
 275. Wu C, Wei Q, Utomo V, Nadesan P, Whetstone H, Kandel R, Wunder JS, and Alman BA. Side population cells isolated from mesenchymal neoplasms have tumor initiating potential. *Cancer Res* 67: 8216–8222, 2007.
 276. Wuchter C, Leonid K, Ruppert V, Schrappe M, Buchner T, Schoch C, Haerlach T, Harbott J, Ratei R, Dorken B, and Ludwig WD. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. *Haematologica* 85: 711–721, 2000.
 277. Xu J, Peng H, Chen Q, Liu Y, Dong Z, and Zhang JT. Oligomerization domain of the multidrug resistance-associated transporter ABCG2 and its dominant inhibitory activity. *Cancer Res* 67: 4373–4381, 2007.
 278. Yagi T, Seo BB, Di Bernardo S, Nakamaru-Ogiso E, Kao MC, and Matsuno-Yagi A. NADH dehydrogenases: from basic science to biomedicine. *J Bioenerg Biomembr* 33: 233–242, 2001.
 279. Yague E, Armesilla AL, Harrison G, Elliott J, Sardini A, Higgins CF, and Raguz S. P-glycoprotein (MDR1) expression in leukemic cells is regulated at two distinct steps, mRNA stabilization and translational initiation. *J Biol Chem* 278: 10344–10352, 2003.
 280. Yamada T, Mori Y, Hayashi R, Takada M, Ino Y, Naishiro Y, Kondo T, and Hirohashi S. Suppression of intestinal polyposis in Mdr1-deficient ApcMin/+ mice. *Cancer Res* 63: 895–901, 2003.
 281. Yamada T, Takaoka AS, Naishiro Y, Hayashi R, Maruyama K, Maesawa C, Ochiai A, and Hirohashi S. Transactivation of the multidrug resistance 1 gene by T-cell factor 4/beta-catenin complex in early colorectal carcinogenesis. *Cancer Res* 60: 4761–4766, 2000.
 282. Yamane Y, Furuichi M, Song R, Van NT, Mulcahy RT, Ishikawa T, and Kuo MT. Expression of multidrug resistance protein/GS-X pump and gamma-glutamylcysteine synthetase genes is regulated by oxidative stress. *J Biol Chem* 273: 31075–31085, 1998.
 283. Yang Y, Chen Q, and Zhang JT. Structural and functional consequences of mutating cysteine residues in the amino terminus of human multidrug resistance-associated protein 1. *J Biol Chem* 277: 44268–44277, 2002.
 284. Yang Y, Liu Y, Dong Z, Xu J, Peng H, Liu Z, and Zhang JT. Regulation of function by dimerization through the amino-terminal membrane-spanning domain of human ABCC1/MRP12. *J Biol Chem* 282: 8821–8830, 2007.
 285. Yin L, Castagnino P, and Assoian RK. ABCG2 expression and side population abundance regulated by a transforming growth factor beta-directed epithelial-mesenchymal transition. *Cancer Res* 68: 800–807, 2008.
 286. Yoshiura K, Kinoshita A, Ishida T, Ninokata A, Ishikawa T, Kaname T, Bannai M, Tokunaga K, Sonoda S, Komaki R, Ihara M, Saenko VA, Alipov GK, Sekine I, Komatsu K, Takahashi H, Nakashima M, Sosonkina N, Mapendano CK, Ghadami M, Nomura M, Liang DS, Miwa N, Kim DK, Garidkhuu A, Natsume N, Ohta T, Tomita H, Kaneko A, Kikuchi M, Russomando G, Hirayama K, Ishibashi M, Takahashi A, Saitou N, Murray JC, Saito S, Nakamura Y, and Niikawa N. A SNP in the ABCC11 gene is the determinant of human earwax type. *Nat Genet* 38: 324–330, 2006.
 287. Yu R, Chen C, Mo YY, Hebbar V, Owuor ED, Tan TH, and Kong AN. Activation of mitogen-activated protein kinase pathways induces antioxidant response element-mediated

- gene expression via a Nrf2-dependent mechanism. *J Biol Chem* 275: 39907–39913, 2000.
288. Zelcer N, Saeki T, Reid G, Beijnen JH, and Borst P. Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3). *J Biol Chem* 276: 46400–46407, 2001.
289. Zelcer N, van de WK, Hillebrand M, Sarton E, Kuil A, Wielinga PR, Tephly T, Dahan A, Beijnen JH, and Borst P. Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception. *Proc Natl Acad Sci U S A* 102: 7274–7279, 2005.
290. Zhang DD. Mechanistic studies of the Nrf2–Keap1 signaling pathway. *Drug Metab Rev* 38: 769–789, 2006.
291. Zhou S, Morris JJ, Barnes Y, Lan L, Schuetz JD, and Sorrentino BP. Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. *Proc Natl Acad Sci U S A* 99: 12339–12344, 2002.
292. Zhou S, Schuetz JD, Bunting KD, Colapietro AM, Sampath J, Morris JJ, Lagutina I, Grosveld GC, Osawa M, Nakauchi H, and Sorrentino BP. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. *Nat Med* 7: 1028–1034, 2001.
293. Zhu J, Blenis J, and Yuan J. Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1. *Proc Natl Acad Sci U S A* 105: 6584–6589, 2008.
294. Zipper LM and Mulcahy RT. Inhibition of ERK and p38 MAP kinases inhibits binding of Nrf2 and induction of GCS genes. *Biochem Biophys Res Commun* 278: 484–492, 2000.
295. Zochbauer S, Gsur A, Brunner R, Kyrle PA, Lechner K, and Pirker R. P-glycoprotein expression as unfavorable prognostic factor in acute myeloid leukemia. *Leukemia* 8: 974–977, 1994.
296. Zong Y, Zhou S, and Sorrentino BP. Loss of P-glycoprotein expression in hematopoietic stem cells does not improve responses to imatinib in a murine model of chronic myelogenous leukemia. *Leukemia* 19: 1590–1596, 2005.

Address reprint requests to:

Dr. M. Tien Kuo

Department of Molecular Pathology (Unit 951)

The University of Texas M. D. Anderson Cancer Center

1515 Holcombe Boulevard

Houston, TX 77030

E-mail: tkuo@mdanderson.org

Date of first submission to ARS Central, April 8, 2008; date of final revised submission, June 18, 2008; date of acceptance, June 21, 2008.